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Glioblastoma is the most common malignant primary brain tumor in adults; the current 
aggressive treatment results in a 5% five-year survival rate. More effective therapies should be 
developed. One promising alternative is oncolytic adenovirus, Delta-24-RGD, which elicits 
cancer cell lysis and immunogenic cell death. In fact, Delta-24-RGD produced complete 
responses in 20% of recurrent glioblastoma patients through immune mechanisms that activate 
anti-tumor cytotoxic properties of T-cells. This cytolytic effect can further be enhanced by adding 
immune agonists, namely OX40L, which engages the OX40 receptor to co-stimulate activated T 
cells for enhanced proliferation. Hence, we produced the next generation of Delta-24-RGD, called 
Delta-24-RGDOX, which expresses OX40L. Our previous publications exhibited enhanced 
immune-activating responses and improved survival in glioma-bearing mice treated with Delta-
24-RGDOX compared to Delta-24-RGD. Nevertheless, maximal survival of glioma-bearing mice 
is unattainable, suggesting the presence of sustained immunosuppression within the glioma 
microenvironment. For example, indoleamine-2,3-dioxygenase (IDO) is upregulated in 
glioblastoma, correlates with poor prognoses, and is a main source of immunosuppression. IDO 
is an IFN inducible enzyme that catabolizes tryptophan resulting in diminished proliferation or 
apoptosis of surrounding effector T cells. Furthermore, kynurenine (Kyn), a tryptophan 
metabolite, induces T-cell differentiation into Tregs. Excess Kyn also activates carcinogenic 
transcription factor, aryl hydrocarbon receptor (AhR), which further mediates lymphocyte 
dysfunction and immunosuppression. Relating to our studies, the immune stimulating effect of 
Delta-24-RGDOX triggers IFN production contributing to a positive IDO-Kyn-AhR feedback 
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loop. Additionally, IDO-mediated tryptophan depletion hinders viral replication. Therefore, we 
hypothesized that combining Delta-24-RGDOX with IDO inhibitors will improve therapeutic 
outcomes and enhance antitumor immune responses of murine glioblastoma. Here, we showed 
that Delta-24-RGDOX activated the IDO-Kyn-AhR cascade in glioma cells. Furthermore, we 
demonstrated enhanced therapeutic effectiveness of combined IDO inhibitor and Delta-24-
RGDOX treatment compared to single agents, which was validated in immunocompetent IDO-
KO mice. The combination treatment efficacy required CD4+ T cell activation and associated with 
increased activation of T cells and decreased Tregs and MDSCs. This microenvironment 
remodeling correlated with complete tumor elimination. Altogether, Delta-24-RGDOX activates 
the IDO-Kyn-AhR cascade, identifying new targets, which when inhibited have the potential to 
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Chapter 1: Background and Significance  
 
I. Glioblastoma 
Brain tumors or gliomas can be divided into four grades based on its histology. The grade 
of gliomas increases proportionally to levels of differentiation or anaplasia and aggressiveness 
(1). The highest grade (IV) of glioma is known as glioblastoma and is the most common malignant 
primary brain tumor in adults. Glioblastoma is characterized by high mitotic activity with 
microvascular proliferation, necrosis, and displays anaplasia. These criteria result in tumors that 
that are very aggressive and are considered malignant. Glioblastoma accounts for 15% of all brain 
malignancies, and accounts for the majority of primary malignant brain tumor cases at 48% (2).  
With the aggressive conventional treatment of maximal surgery, radiation, and adjuvant 
chemotherapy, such as temozolomide, the 5-year survival rate remains around 5% and the median 
survival is approximately 15 months (3). Recurrence often occurs within 6-12 months because the 
tumors are molecularly heterogeneous and the blood-brain barrier is an obstacle for therapeutic 
penetration (4). In addition, brain tumors can often employ mechanisms of immunosuppression, 
discussed below, which allow for further tumor progression. At present, patients with recurrent 
glioblastoma can be treated with bevacizumab which targets vascular endothelial growth factor 
(VEGF), and is often used in combination with Lomustine, a DNA alkylating chemotherapy (5). 
Other FDA approved treatments for recurrent glioblastoma includes alkylating agent, Gliadel (6), 
and Novocure, a device that can be worn as a helmet, and uses electric fields, called Tumor 
Treating Fields (7), to treat the solid tumor.  Despite the advances made in this field in the past 
decades, the survival rates and mortality statistics have remained the same. The need for more 
effective therapies to treat both primary and secondary glioblastomas is apparent. 
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II. Immunosuppressive Environment of Glioma 
Glioblastoma employs various immunosuppressive mechanisms, leading to its 
maintenance and progression. Glioblastoma elicits immunosuppression through secretion of 
cytokines, employment of immune checkpoints, and modulation of different cell types in the 
tumor microenvironment. These mechanisms are often dependent on each other, creating an 
immune microenvironment that is favorable for tumor growth.  
Glioblastoma cells secrete immunosuppressive cytokines including, transforming growth 
factor beta (TGF-β), interleukin (IL)-10, and IL-1, all of which are important in the prevention of 
autoimmune diseases (8). Glioblastoma also secretes colony stimulating factor 1 (CSF-1) (9), 
which elicits the immunosuppressive M2 phenotype in tumor associated macrophages and thus 
leads to a glioma-enhancing environment (10). Adding to the immunosuppression is the secretion 
of granulocyte-macrophage-CSF, important for granulocyte and macrophage function, which can 
induce the activation of myeloid derived suppressor cells (MDSCs) (11).  
Inhibition of immune activating cells is another method employed by glioblastoma for 
maintenance of immunosuppression. For example, differentiated dendritic cells are inhibited by 
the secretion of VEGF. Dendritic cells are important antigen presenting cells that present antigens 
in the context of major histocompatibility complex (MHC), which is required for T-cell activation 
(12). Additionally, natural killer cells are inhibited by the secretion of regeneration and tolerance 
factor (RTF) (13). 
  Studies have shown that the expression of immune checkpoint regulators are increased 
on glioblastoma cell surfaces and surrounding T cells. Cytotoxic T-Lymphocyte-associated 
protein 4 (CTLA-4) is a substantial negative regulator of the immune system and has been seen 
to be associated with many cancers, particularly melanoma (14). The activation of CTLA-4 
normally functions to regulate over-activity of the host immune system. In the context of cancer, 
3 
 
the expression and activation of CTLA-4 will keep the cancer microenvironment suppressed, 
allowing for unchecked tumor growth. Activation of T cells requires two basic signals: 1) the 
recognition of the antigen presented in the context of MHC by the T-cell receptor and 2) a co-
stimulation signal. This secondary co-stimulation signal includes the interaction of a CD28 family 
receptor of the T cell and a ligand of the B7 family of the target cell, such as a tumor cell or 
antigen presenting cell. However, the signal conferred by CTLA-4, a member of the CD28 
receptor family, and a B7 protein renders an inactive co-stimulation signal, and will not implement 
T-cell responses. Thus, CTLA-4 suppresses T-cell responses against tumor cells allowing tumor 
growth (15).  Programmed death ligand 1 (PD-L1) is also expressed on glioblastoma cells and can 
interact with the negative regulating receptor, programmed death 1 (PD-1), which is expressed on 
T-cells, to suppress its activity (16). 
Regulatory T-cell (Treg) activation also aids in immunosuppression of glioblastoma. 
Glioblastoma produces the chemokine C-C ligand 2, which triggers and traffics Tregs to the tumor 
site (17). Additionally, Tregs can be activated through the metabolism of tryptophan (Trp) by the 
enzyme, indoleamine-2,3-dioxygenase (IDO) (18).  
Signal transducer and activator of transcription 3 (STAT3) is ubiquitously expressed in 
glioblastoma cells (19). Blockade of STAT3 can upregulate immune activating cytokines, 
including IL-6; the presence of hypoxia enhances this pathway, which is a hallmark of many 
cancers, including glioblastoma (20). As such, under hypoxic conditions, VEGF signaling 
increases, adding to the immunosuppressive and tumorigenic nature of glioblastoma (21). 
The mechanisms that glioblastoma cells engage to produce an immunosuppressive 
environment are complex. Understanding these mechanisms will allow for new immuno-




III. The IDO Pathway 
As mentioned above, IDO is a contributing factor to the immune suppression visible in 
glioblastoma patients. IDO was originally discovered in the placenta of pregnant mice, as a 
mechanism of immune tolerance against their fetuses during gestation (22). In the context of 
cancer, the catabolism of Trp to kynurenine (Kyn) results in various immunosuppressive 
pathways allowing the tumor to progress. Of relevance, studies have shown that patients with high 
expression of IDO have a poorer prognosis and a diagnosis associated with higher grade brain 
tumors, including glioblastoma (23). While three enzymes, Tryptophan-2,3-dioxygenase (TDO), 
IDO, and Indoleamine-2,3-dioxygenase 2 (IDO2), regulate the conversion of Trp into downstream 
Kyn, TDO is expressed in the liver and neurons and thus its pharmacological targeting may induce 
unacceptable toxicity (24), and IDO2, for which expression pattern there are fewer reports, has a 
significantly lower enzymatic activity than IDO (25, 26). Hence, most studies targeting the IDO 
pathway do not explore IDO2 or TDO.  
IDO can be expressed by tumor cells, dendritic cells, and stromal cells. The enzyme can be 
activated via engagement of type I and II interferons, oncogenic ligand-receptor signaling 
complexes, pathogen associated molecular patterns, PD-1/PD-L1 signaling, or B7 co-stimulation 
signals. Immunosuppressive properties of TGF-β have also been implicated in activation of IDO 
(27). IDO-mediated tumor-associated immunosuppression is explained by the local depletion of 
Trp and, consequently, the excess of Kyn in the tumor microenvironment (23, 27-31). 
Downstream Kyn accumulation contributes to the conversion of naive CD4+ T cells into 
immunosuppressive FOXP3-expressing regulatory T cells by virtue of the interaction 
between Kyn and the aryl hydrocarbon receptor (AhR) (32, 33). In addition, T effector cells that 
sense Trp deprivation via the IDO pathway can activate stress kinase signals via GCN2 (general 
control nonderepressible 2), resulting in phosphorylation of eIF2 (Eukaryotic Initiation Factor 2), 
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which is a key translation regulator that delays translation and stimulates the integrated stress 
response pathway, resulting in cell cycle arrest or apoptosis of these effector T cells (27, 34, 35).   
Moreover, this integrated stress response pathway can lead to transcription and expression of 
various inflammatory cytokines, such as IL-6 (36), which has been shown to be essential in both 
IDO-mediated MDSC formation and tumor growth (37). The deprivation of Trp can also be 
sensed by amino acid sensing kinase GLK1, which can control mammalian target of rapamycin 
complex 1 (mTORC) responses in T effector cells; in environments of low tryptophan, mTORC1 
signaling is inhibited, which in turn, blocks the phosphorylation of ribosomal kinase S6K, which 
is involved the process of translation (27, 38). In summary, the activation of IDO employs various 
mechanisms of immunosuppression. 
Although brain tumors can be targeted by different types of anti-cancer therapies, any anti-
tumor effects can be counteracted by IDO-mediated metabolic and immune suppression 
mechanisms to maintain the deep immunosuppressive environment in the core of gliomas. Further 
studies have shown how the inhibition of IDO, which may, in itself, be insufficient to reverse the 
tumor immunosuppression, but dramatically improves the responses of other common cancer 
therapies, most likely due to the conversion by conventional therapies of non-immunogenic 
“cold” tumors to immunogenic “hot” tumors, exposing the targets necessary for efficacy of IDO 
inhibition (27, 39-41).  
 
IV. The AhR pathway 
The deep immunosuppression caused by IDO can be further enhanced by the activation of 
downstream receptor, AhR. The production of Kyn by an active IDO enzyme can bind AhR, 
resulting in both the expression and activation of IDO, generating a highly immunosuppressive 
IDO-Kyn-AhR positive feedback loop.  In fact, the IDO-Kyn-AhR circuit is a key player in the 
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immunosuppression of the microenvironment of gliomas and other tumors (28, 29). Reports have 
shown that the levels of IDO, Kyn, and AhR are increased in gliomas. This is important because 
the activation of IDO and AhR in the tumor microenvironment cooperate to suppress tumor-
specific responses, promoting glioma immune evasion and tumor progression (32, 33).  For 
example, agonists of AhR, including Kyn, can directly aid in the differentiation of naïve CD4+ T 
cells to the immunosuppressive regulatory T cell via elicitation of the immunosuppressive 
cytokines, IL-10, TGF-β, and VEGFA (29).  
When AhR is bound to its activating ligand, such as Kyn, it undergoes a conformational 
change that allows it to move into the nucleus to dimerize with its translocator partner, ARNT, 
which in turn binds to dioxin responsive elements that lead to the transcription of its target genes 
including enzymes from the cytochrome P450 family, like CYP1A1, CYP1A2, and CYP1B1 (42). 
These enzymes have been implicated in the metabolism and bioactivation of carcinogens, 
including polycyclic aromatic hydrocarbons, which occur naturally in coal, crude oil, and gasoline 
(43).  Interestingly, increased CYP1B1 mRNA expression is correlated with a poor glioblastoma 
prognosis (44).  
The activation of AhR also leads to the transcription of certain histone deacetylases including, 
HDAC1, which have been implicated in tumorigenesis (45). Furthermore, AhR can induce an 
inflammatory signal via IL-6 through dioxin responsive elements. This inflammatory signal can 
recruit different inflammatory mediators and growth factors to the tumor cell, allowing it to 
undergo growth and proliferation; in addition, these mediators and growth factors can also elicit 
CD4+ T cell differentiation into the Treg cell via the same immunosuppressive cytokines (IL-10, 
TGF-β, and VEGFA) utilized by Kyn (29). Activation of the IDO-Kyn-AhR cascade also 
activates immunosuppressive macrophages; more specifically, AhR has been reported to drive 
expression of ectonucleotidase, CD39, in tumor associated macrophages, which can cause the 
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dysfunction of cytotoxic CD8+ T cells by producing adenosine which cooperates with CD73, 
which has recently been reported to be involved in T-cell co-signaling (46). 
 The mechanisms of immunosuppression employed by the IDO-Kyn-AhR cascade are 
implicated in glioblastoma; this pathway provides several druggable targets that can aid in 
improved prognoses of patients with glioblastoma.  
 
V. Targeting the IDO Pathway 
 IDO has been reported to be overexpressed in various cancers including those of the 
cervix, kidney, lung, colon, (47) and brain (23). Moreover, IDO has been reported to protect 
mouse tumors from immune rejection (18). Naturally, this has led to pre-clinical studies targeting 
IDO as a treatment for cancer. There have been many reports of the use of IDO inhibitors 
providing a therapeutic benefit in various mouse models of cancer when combined with cancer 
vaccines, immune checkpoint inhibitors, or chemotherapy (18, 48-51). Of relevance, Wainwright 
and colleagues showed a durable therapeutic effect of using a triple therapy that blocked IDO, 
CTLA-4, and PD-L1 in a murine glioblastoma model (52). These numerous studies led to the 
development of several IDO inhibitors to be used in the clinic (53).  
Currently, two classes of IDO inhibitors are being used. The first class includes Trp-mimetics, 
including Indoximod (1-methyl-D-tryptophan) and 1MT (1-methyl-D, L-tryptophan). Although 
the mechanism of Indoximod and 1MT are not fully understood, the negative regulation of 
mTORC signaling in T effector cells caused by tryptophan depletion of IDO activation can be 
restored with these drugs (54). As such, Indoximod is currently being tested in phase II clinical 
trials in combination with cancer vaccines, chemotherapies, or immune checkpoint inhibitors in 
various cancer types including leukemia, melanoma, pancreatic, breast, and other solid tumors 
(53). A phase I/II study of the use of adenovirus-p53 transduced dendritic cell vaccine combined 
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with Indoximod in patients with metastatic solid tumors showed that patients tolerated a 
maximum dose of 1600 mg BID with no severe toxicities; determinations of efficacy are 
warranted by future trials.  
The second class of IDO inhibitors are direct IDO enzyme inhibitors including, Epacadostat, 
Navoximod, and BMS-986205, which can shut off any downstream targets of IDO activation 
including both the Kyn pathway and the amino acid deprivation stress pathways (27). The most 
advanced direct IDO enzyme inhibitor is Epacadostat, which showed encouraging results in 
patients with advanced melanoma when treated in combination with PD-1 blocking antibody, 
pembrolizumab, in phase I/II trials (55).  This prompted the start of a large phase III trial (ECHO-
301/KN-252) testing this combination in patients with advanced melanoma. The trial was later 
closed when initial results from the study showed no therapeutic benefit when comparing the 
combination to pembrolizumab alone (56). Intrinsically, this has somewhat dampened the interest 
to use IDO inhibitors in the clinic. However, the failure of this drug in the phase III setting may 
be attributable to dosing issues or inappropriate patient selection. More investigations that can 
elucidate which patients will most likely benefit from IDO blockade is essential. Additionally, the 
reported poor prognoses in cancer patients with high IDO expression along with the supporting 
pre-clinical evidence demonstrating the anti-cancer effects by targeting IDO with other anti-
cancer drugs warrant further investigation and the continuation of targeting IDO in cancer.   
Other novel IDO enzyme inhibitors are also being investigated in pre-clinical models. For 
example, Ladomersky and colleagues demonstrated that the use of triple therapy of CNS-
penetrating IDO enzyme inhibitor, BGB-5777, combined with a PD-1 monoclonal antibody and 
radiotherapy was more therapeutically beneficial then single agents or any dual therapy 
combination in a mouse model of glioblastoma (39). The same group was able to validate these 
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results using the clinical grade version of BGB-5777, called BGB-7204 (57), which has been used 
in some studies of this dissertation.  
 
VI. Viral Infection and IDO 
There have been reports of increased IDO expression and activity during human 
immunodeficiency virus (HIV), influenza, hepatitis B virus (HBV), or hepatitis C virus (HCV) 
infection (58). This induction of the IDO pathway by these viruses is generated by both type I and 




There have been several reports linking the IDO pathway to HIV-infected patients. These 
patients show increased serum levels of both IFNγ and Kyn (59). Elevated IDO mRNA levels 
have also been seen in the peripheral blood mononuclear cells (PBMCs) of patients infected with 
HIV (60). One study found that HIV infection of PBMCs in vitro leads to secretion of type I 
interferons, IFNα and IFNβ, which was associated with IDO expression and activity (61). In these 
same cultures, the use of Trp-mimetic, 1MT, led to the increase of CD4+ and CD8+ T cell 
proliferation (60, 61), indicating the immunosuppression aided by IDO. Similarly, IDO enzyme 
activity was associated in the antigen presenting cells of HIV-infected patients to reduce anti-viral 
T cell responses via regulatory T cells (62).   
 
Influenza 
 Studies have shown that mouse influenza can induce IDO expression in mouse lung tissue 
and nearby lymph nodes (63, 64). Similar to HIV, the mouse influenza virus, X31, induced IFNγ 
secretion in the lymph nodes leading to increased IDO production in surrounding non-
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hematopoietic cells (64). The treatment of influenza infected mice with 1MT also increased the 
number of functionally active CD4+ T cells and virus-specific memory CD8+ T cells (65) and 
enhanced Th1 responses via IFNγ secretion by CD4+ and CD8+ T cells (66), indicating the 
immune suppression caused by IDO under influenza virus infection.   
  
HBV and HCV 
 IDO has also been implicated in patients with HBV and HCV chronic infections (67). 
These patients also had high systemic Kyn/Trp ratios in their blood compared to healthy controls 
(68). In vitro studies demonstrated that PBMC monocytes from HCV patients led to 
differentiation of IDO-positive dendritic cells that induced regulatory T cells by LPS or IFNγ 
more potently compared to healthy controls (67), again indicating the immunosuppression caused 
by IDO.   
 
Adenovirus 
 Like the viruses mentioned above, IFN activation is triggered by sensing of adenoviral 
DNA in the cell. For example, the immune responses by adenoviruses include elicitation of IFNα 
via MyD88 signaling of TLR9 (69). Furthermore, IFNβ induction by the adenovirus is required 
for viral functions including entry, endosomal escape, and release of the viral DNA into the 
cytoplasm (70). While type I IFNs, IFNα and IFNβ, are secreted by adenovirus-infected cells, 
IFNγ is produced by T cells and NK cells and plays an important role in cell-mediated immunity 
against adenoviruses (71). IFNγ induces an antiviral state so that adenoviral replication is 
inhibited. However, E1A gene products can suppress transcription of IFNγ (72). These contrasting 
effects of IFNγ by adenoviruses and the T cells or NK cells may represent an example 
evolutionary reaction between virus and host. As mentioned above, these IFN responses 
associated with adenoviral infection are also directly related to the expression and activation of 
IDO. In fact, one report showed that stimulation of dendritic cells with IFNα significantly 
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upregulated IDO expression (73). In this dissertation, we show that modified oncolytic 
adenoviruses increase the expression and activation of IDO in various human and mouse models 
of cancer, including glioblastoma. Furthermore, we demonstrate that these modified oncolytic 
adenoviruses also activate the downstream pathway of IDO, AhR.   
 
VII. Adenovirus Structure and Life Cycle 
The structure of the adenovirus is conferred by its genome, which is comprised of about ~ 
36 kb of linear double stranded DNA. Adenoviruses are classified as non-enveloped and are about 
95 nm in size (157 MDa). They have an icosahedral shaped capsid composed of 240 copies of the 
hexon protein (II) and 12 penton (III) capsomeres with fiber proteins (IV) attached. Minor capsid 
proteins include protein IIIa, VI, VIII, and IX, which stabilize the viral capsid structure and are 
involved in endosomal escape and transcriptional activation. Core proteins include the terminal 
proteins, V, VII, and mu, all of which interact with the viral DNA to condense it (74).  
To start infection, the knob domain of the fiber protein binds to the coxsackie adenovirus 
receptor (CAR) or the CD46 receptor to stimulate internalization via clathrin-coated pits. The 
fibers shed allowing the endosome to internalize the uncoated virus. Acidification of the 
endosome disassembles the viral capsid further, leading to the release of internal proteins into the 
endosome. Then, activated viral proteases cleave protein VI, which lyses the endosome to 
facilitate viral escape. The partially uncoated virus consequently moves to the nuclear pores via 
microtubules with the help of protein VII (75).  
After this infection into the nucleus, E1A transcription occurs and stimulates the 
transcription of all early viral genes, which affects the transcription profile of the host cell. E1B-
55K then inhibits p53-induced apoptosis and E1B-19K binds to the BCL-2 family protein 
complex BAK-BAX, preventing the formation of mitochondrial pores. After E1A activation, 
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transcription of the E3 gene occurs, which encodes for several proteins that inhibit the host innate 
and acquired immune response to viral infection. The E4 region has 7 open-reading frames, which 
stimulate the production of cellular translational factors, inhibits the cellular DNA double-strand 
break response, forms a complex with E1B-55K to inhibit p53, and recruits the cellular 
transcription factors to the E2 promoter. The transcription of the E2 region occurs last, and codes 
for adenoviral DNA polymerase, ssDNA binding protein, and the preterminal protein, all of which 
are required for viral replication (76).  
After completion of viral replication, the synthesis of major capsid proteins occurs in the 
cytoplasm. Hexon, fiber, and penton assemble into multimeres in the cytoplasm and transport to 
the nucleus. With the support of the L1 52/55k protein, the Iva2 protein facilitates DNA packaging 
of the virion. DNA packaging is associated with core protein precursors, including protein VI, 
VII, VIII and mu. The viral protease cleaves these precursors to produce mature viral particles 
(77). The E3-11.6 kDa protein promotes release of these viral particles. These viral particles 
interact with the MAD2B gene to promote cell lysis and the consequent infection of surrounding 
cells to perpetuate its life cycle (78). 
 
VIII. Delta-24 and Delta-24-RGD 
The easy manipulation of the adenovirus makes it a good candidate for oncolytic viral 
therapy.  Adenoviruses can be easily modified for attenuation, specificity, and cytotoxicity against 
tumor cells. In 2000, our group developed tumor selective adenovirus, Delta-24, which relies on 
the retinoblastoma (RB) pathway dysregulation, that is present in ~80% of glioblastomas, for viral 
replication (79, 80). For adenoviral replication to occur, E1A must bind Rb to release it from E2F, 
resulting in cell cycle entry through activation of the E2 promoter (81). Delta-24 contains a 24 
base pair deletion of the E1A gene producing a mutant E1A, making it unable to bind Rb. This 
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deletion confers specificity to cancer cells since the binding of E1A to Rb will not occur in normal 
cells due to a defective E1A protein manifested by the 24bp deletion; thus, replication of the virus 
will be inhibited in normal cells. Contrastingly, the Rb pathway is dysregulated in glioblastoma 
cells, which allows the cancer cells proliferate uncontrollably; the viral life cycle of Delta-24 can 
take advantage of this and will be able to replicate (82).  
Infection and internalization depend on viral binding to the coxsackie adenovirus receptor 
or the CD46 receptor (83). However, glioma cells do not normally express these receptors. Thus, 
to increase the tropism of the adenoviruses to glioblastoma cells, the RGD motif was added at the 
carboxyl end of the fiber protein of Delta-24 to produce the next generation virus called Delta-
24-RGD (84). The RGD motif can bind to RGD-related integrins, such as the αvβ3 and αvβ5 
integrins (85), of which are highly expressed on glioblastoma cells (86). 
Once infection of cancer cells occur, Delta-24-RGD can cause oncolytic lysis through 
autophagy and immunogenic cell death. In vitro and in vivo studies show an increase in autophagy 
mediators (87), which is thought to be associated with inhibition of the AKT/TOR pathway (88). 
The effect of autophagy made by the adenovirus may be thought of as an innate immune response 
because of viral clearance. Moreover, the immune response is increased by proteasome activity, 
which generates tumor associated antigens that can be presented in the context of MHC to 
cytotoxic CD8+ T-Cells (89).  
Our group recently published results from a Phase I clinical trial testing Delta-24-RGD in 
patients with recurrent glioblastoma. This trial resulted in 20% of patients living past three years. 
Furthermore, the patients who responded portrayed radiographic signs of inflammation, or a 
pseudoprogression, followed by a response. Moreover, the clinical trials indicate that part of the 
oncolytic virus-mediated anti-glioma effect was due to an anti-tumor immune response as 
indicated by the obvious infiltration of immune cells seen in the H&E staining from patient 
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biopsies after treatment with Delta-24-RGD. Moreover, these same biopsies of the glioblastoma 
in the patients’ post-virus treatment showed infiltration of CD8+ and T-bet T cells, indicating the 
elicitation of a Th1 immune response. Importantly, further histological staining indicated that the 
virus was cleared within a month of infection. These responses indicate that the anti-viral response 
triggered an immune response against the virus and the tumor (90).  
One trial (NCT02798406) is currently testing therapeutic efficacy of the combination 
therapy of Delta-24-RGD with pembrolizumab, the PD-1 monoclonal antibody, in glioblastoma 
patients. The anti-tumor response will be coupled with the inhibition of immunosuppression aided 
by PD-1 for a robust immune response against the tumor. 
 
IX. Delta-24-RGDOX 
To increase the immune response of Delta-24-RGD, our group developed the next 
generation virus, called Delta-24-RGDOX. Delta-24-RGDOX is similar to Delta-24-RGD, in that 
it contains the 24 bp deletion in the E1A gene and the addition of the RGD motif, as previously 
mentioned. Unlike Delta-24-RGD, Delta-24-RGDOX also contains the OX40-ligand (OX40L) 
expression cassette, allowing for expression of this immune agonist on infected cancer cells (91). 
OX40L is part of the tumor necrosis factor receptor/tumor necrosis factor family and is expressed 
on activated CD4+ and CD8+ T cells, serving as costimulatory signals to promote the proliferation 
and clonal expansion of effector and memory T cells (92, 93). Thus, the expression of OX40L on 
cancer cells transforms the cancer cells into an ad-hoc antigen presenting cell, thus enhancing the 
proliferation of activated T cell clones that can recognize cancer antigen.  
Preclinical studies, performed in our lab, indicate that Delta-24-RGDOX is more 
therapeutically effective than Delta-24-RGD in a glioblastoma immunocompetent murine model. 
Furthermore, when tested in an immune deficient model, the therapeutic efficacy of both Delta-
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24-RGD and Delta-24-RGDOX is completely eradicated. Additionally, we observed that Delta-
24-RGDOX provides a more robust anti-viral and anti-tumor immune response compared to 
Delta-24-RGD as indicated by functional co-culture experiments utilizing the brain infiltrating 
lymphocytes from these glioblastoma bearing virally treated mice. Moreover, Delta-24-RGDOX 
elicited a more immunogenic tumor microenvironment compared to Delta-24-RGD as indicated 
by an increase in CD3+, CD4+, and CD8+ T cells (91). Our studies also showed that Delta-24-
RGDOX increased expression of both MHC1 and MHCII expression on infected cancer cells, 
indicating that these tumor cells can act as antigen presenting cells (94). Interestingly, Delta-24-
RGDOX also increases expression of PD-L1 and PD-1 expression within the microenvironment. 
In fact, the combination of Delta-24-RGDOX and PD-L1 antibodies is more effective in treating 
murine glioma than Delta-24-RGDOX alone. This indicates that despite the cytotoxic T cell 
responses, immune suppression can still be present in Delta-24-RGDOX treated tumors (91).  PD-
L1 engagement has been implicated in IDO activation, which adds to our speculation that Delta-
24-RGDOX can elicit mechanisms of immunosuppression. As such, Delta-24-RGDOX has 
shown to be a good candidate for various combination treatments, including IDO inhibitors. 
Glioma is a non-metastatic localized disease, which allows the intra-tumoral injection 
within the brain, which will not cause any potential systemic infection. The ease in manipulation 
of adenovirus led to the construction of the non-pathogenic Delta-24-RGDOX, which has an 
increased tropism to glioma cells and elicits a stronger anti-tumor immune response compared to 
its predecessor. The non-lymphocytic nature of the brain increases the chance of viral infectivity, 
and thus oncolysis. In addition, Delta-24-RGDOX can elicit an immune response, which can start 
off as a response for viral clearance and transform into immunity against the tumor. This 
observation, which is also common among other oncolytic viruses (95-98), has led to the paradigm 
shift that oncolytic virotherapy should be considered a type of immunotherapy. Stated more 
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explicitly, Delta-24-RGDOX can elicit a positive immune response against the tumor by 
transforming a non-immunogenic tumor microenvironment (glioblastoma) into an immunogenic 
one. This perspective is leading the field to discovering combination treatments with oncolytic 
viruses that will synergize with current immunotherapies to increase anti-tumor immunity. 
 
X. Current Landscape of Oncolytic Viruses as Clinical Treatments in Glioma  
 
In addition to the adenovirus (90) family, other families of viruses have been heavily clinically 
studied including the herpes simplex virus type I (98-101), reovirus (102-104), Newcastle Disease 
virus (105-108), and poliovirus (97). The measles virus (NCT00390299), vaccina virus 
(NCT03294486), and the parvovirus (109) have also been tested clinically, however there are 
currently no reports assessing their effect on patient survival. The benefits of oncolytic 
virotherapy in the treatment of cancers including glioblastoma is that the viruses can elicit cancer 
cell death using multiple methods including oncolysis and immunogenic cell death. For example, 
upon viral infection, the innate and adaptive immune response can be elicited by danger- and 
pathogen-associated molecular patterns (110). The result is an anti-viral immune response that 
could also elicit an anti-tumor immune response. In fact, some common effects of treatment of 
glioblastoma with different oncolytic viruses includes the induced immunogenicity. Inherently, 
this provides a hurdle for oncolytic therapy because the increased immunogenicity is initially 
directed towards removing the pathogen from the host. As such, the effectiveness of oncolytic 
viruses depends on the balance between the anti-viral immune responses and the virus mediated 
anti-tumor immune responses. Despite this obstacle, there have been major strides demonstrating 





Herpes Simplex Virus Type 1 (HSV1) 
HSV1 belongs to the Herpesviridae family and is composed of dsDNA that encodes 81 
viral genes. For attenuation and specificity three genes are often deleted and include, dlsptk, ү34.5, 
and UL39. dlsptk encodes the gene for thymidine kinase, an enzyme that aids in the generation of 
thymidine monophosphate, which is important in the process of DNA replication. The deletion of 
dlsptk is not sufficient for attenuation, as this single mutation can still cause neuropathogenicity. 
Thus, both copies of ү34.5 are often deleted for generation of the oncolytic HSV (111). ү34.5 
encodes the gene for ICP34.5. The function of ICP34.5 is two-fold. First, ICP34.5 can recruit 
protein phosphatase 1 for the dephosphorylation of phosphorylated eIF2α which leads to the 
activation of protein synthesis. Phosphorylated eIF2A, thus, inhibits protein synthesis, which is 
an anti-viral defense mechanism that is mediated by host RNA-induced protein kinase R (112). 
Second, ICP34.5 forms a complex with proliferating cell nuclear antigen, which aids in DNA 
replication and repair (113). The deletion of ICP34.5 thus will decrease the ability of the HSV1 
to undergo both DNA replication and translation. This modification also confers specificity 
because HSV1 mutants do not depend on ICP34.5 for replication in tumor cells. However, in 
normal cells ICP34.5 is crucial for viral replication (114-116). UL39 encodes the gene ICP6, 
which translates to the large subunit of ribonucleotide reductase (117, 118). Ribonucleotide 
reductase functions to increase the dNTP pools of cells for DNA replication. However, in cancer 
cells, the dNTP pools are quite abundant and thus do not depend on ribonucleotide reductase for 
replication (119). Thus, this mutation confers specificity because the lack of a functional 
ribonucleotide reductase in normal cells will not allow for the replication of the viral DNA.  
Currently, there are four different oncolytic HSVs being tested in clinical trials. These 
include HSV1716, G207, rQNestin34.5, G47Δ, and M032. HSV1716 contains the deletion of 
both alleles of ү34.5. HSV1716 has been tested in four clinical trials. All these clinical trials show 
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the safety of this attenuated virus. Of the available data, HSV1716 show survival of patients for 
14-24 months after treatment in 11 of 21 GB patients (99, 101, 120). G207 contains the deletion 
of both alleles of ү34.5 and a lacZ gene insertion in the ICP6 gene. G207 has been tested in three 
Phase I clinical trials in a total of 36 patients of malignant glioma (98, 100, 121). The trials show 
the safety of the attenuated virus. Although tumor decreases were seen in 11 of 36 patients, the 
median survival was not ameliorated compared to results from use of conventional therapy. The 
treatment of glioma using G207 before and after resection yielded a median survival of 6.6 months 
(100).  The use of G207 preceding irradiation yielded a median survival of 7.5 months (98). 
Despite these data, some patients can benefit greatly from G207, and MRI images suggest anti-
tumor activity (121). This anti-tumor effect may be attributed to the anti-tumor immune response. 
GB patients that receive G207, resections show increases in CD3+, CD8+, and HAM56+ immune 
cells suggesting both an innate and adaptive immune response against the tumor (100). In a 
different patient cohort, G207 showed a 20% response rate in pediatric patients with high-grade 
glioma, with a median overall survival of 12.2 months, which is higher than the medial overall 
survival of the primary disease (122). Two other oHSVs are also in Phase I clinical trials and 
include rQNestin34.5, G47Δ, and M032, but the data from these open trials are unpublished. 
rQNestin34.5 was developed to increase replication in GB cells through the reinsertion of one 
copy of ү34.5 into the UL39-deleted, ү34.5-delted viral genome, which is controlled by the nestin 
promotor (123). G47Δ is an extension of G207 and contains the deletion of the α47 gene, which 
increases MHC class I expression to aid in mediation of antigen presenting for T lymphocytes 
(124). M032 lacks both copy of γ34.5 and expresses IL-12 to increase the antigenic stimulation 
response of the tumor microenvironment (125).  G47Δ and M032 are relatively new to the clinic, 
but the pre-clinical data show that they can modulate the immune system for a greater cytotoxic 





 Of the Reoviridae family, reovirus is a non-enveloped RNA virus that can cause 
asymptomatic or mild intestinal infections in human beings. The reovirus is considered to be a 
natural oncolytic virus because it specifically replicates in cells that employ RAS activation, 
which include glioma cells (126). Pre-clinical studies revealed that reovirus can elicit complete 
regression in subcutaneous and intracranial glioma mouse models (127), and can elicit increased 
T-cell infiltration and Type I IFN responses (104). The clinical translation of reovirus into the 
clinic revealed that this virus produces no adverse effects (102, 103), and generated increased 
tumor leukocyte infiltration along with upregulated expression of IFN, caspase 3, and PD-L1 
within the brain tumor of the treated patients (104).   There are currently no reports assessing the 
survival of glioblastoma patients being treated with reovirus. 
 
Newcastle Disease Virus (NDV) 
 Of the Paramyxoviridae family, NDV encapsulates negative sense, single-stranded RNA. 
Because NDV infects mainly avian species, there is minimal pathogenicity in human beings (128). 
The replication of NDV depends on deficiencies of the type I IFN response (107, 129). 
Furthermore, published reports described the requirement of GTPase Rac1 for the replication of 
NDV; GTPase Rac1 maintains glioblastoma stem properties (130, 131). Pre-clinical studies 
revealed that NDV provides an enhanced anti-cancer effect in type I IFN-deficient glioblastoma 
cells (132).  Still, the use of glioblastoma mouse models showed the apoptotic and therapeutic 
effect of NDV either alone or in combination with temozolomide (133-136). NDV has been tested 
in several studies ranging from phase 0 to phase II. The use of the mesogenic strain of NDV called 
MTH-68/H for the treatment in human high-grade glioma resulted in survival rates lasting 5-9 
years (105). Similarly, there was an increase in overall survival in patients with recurrent glioma 
after treatment with NDV infected dendritic cells (107). A different phase I/II study testing a 
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lentogenic NVD strain called OV001/HUJ revealed a 7% complete response rate in patients with 
recurrent glioblastoma (106).  
 
Poliovirus 
 Of the Picornaviradae family, polioviruses encapsulate single strand RNA. Unattenuated 
polioviruses generate neurotoxicity. To make polioviruses clinically relevant, Gromeier and 
colleagues developed an unattenuated polio–rhinovirus chimera, called PVSRIPO, which 
replaced the internal ribosome entry site of the Sabin strain of the poliovirus vaccine with the non-
virulent human rhinovirus type 2 (137). Pre-clinical studies of PVSRIPO proved its ability to 
infect and kill glioma cells both in vitro, which was associated with enhanced survival of glioma 
bearing mice in vivo (138-140). Results from an interventional study testing PVSRIPO in 61 
patients with recurrent glioblastoma showed 21% of patients surviving after 36 months (97). A 
phase II study (NCT02986178) and a phase Ib study (NCT03043391) are currently ongoing.  
 
 
XI. Hypothesis and Aims 
 
Glioblastoma is the most common malignant primary brain tumor in adults. Conventional 
treatment of glioblastoma includes chemotherapy, radiotherapy, and surgery. However, upon 
diagnosis, and with the aggressive conventional therapies, the median survival is about 15 to 17 
months (2). Alternative forms of glioma therapy are crucial. Oncolytic viruses (OV) provide a 
promising alternative to current treatment because it induces cell death by several cytotoxic and 
immune mechanisms that stem from direct lysis (141, 142). In addition, because apoptosis is not 
the OV’s mode of killing, apoptosis-resistant glioma cells are not the basis of recurrence. Delta-
24-RGD is an OV that is highly replicative and tumor specific (89, 143). Delta-24-RGD has been 
translated to the clinic and was tested in Phase I and II clinical trials. Recently published data 
from a Phase I Study show that treatment of recurrent glioblastoma with Delta-24-RGD led to 
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complete tumor regression in 20% of patients (90). Moreover, the clinical trials indicate that part 
of the OV-mediated anti-glioma effect was due to an anti-tumor immune response, as indicated 
by the presence of pseudoprogression and an infiltration of CD8+ T cells. In this regard, pre-
clinical studies of Delta-24-RGD in glioblastoma have shown that in addition to the production 
of pathogen associated molecular patterns, the adenovirus infection induces autophagy, a 
mechanism underlying antigen presentation and immunogenic cell death with production of 
damage associated molecular patterns (89, 143). Thus, the Delta-24-RGD infection of the cancer 
cells elicits an anti-viral immune response that eventually becomes an anti-tumor immune 
response in a small percentage of patients. Further enhancement of the immune component of 
oncolytic viral therapy should increase the percentage of glioblastoma patients sensitive to Delta-
24-RGD. One approach to increase the cytotoxic immune response consists of the modulation of 
T-cell immune checkpoints (41). Based on this tenet, our group recently generated an immune-
agonist armed version of Delta-24-RGD, named Delta-24-RGDOX, which express the immune 
co-stimulatory molecule, OX40L, a member of the tumor necrosis factor superfamily, and is a 
positive regulator or agonist of the immune synapsis and enhances the activation and proliferation 
of cytotoxic T-cells through co-stimulation (92, 93, 144). Our recently published data show that 
Delta-24-RGDOX has a superior anti-tumor effect compared to Delta-24-RGD in an orthotopic 
glioblastoma immunocompetent mouse model (91). We hypothesize that Delta-24-RGDOX will 
directly enhance the activity of cytotoxic T-cells against glioblastoma. We are also taking into 
consideration that a positive activation of lymphocytes can be halted by the immune suppressive 
tumor microenvironment. For example, T-cell anergy can occur when the T-cell receptor engages 
the MHC-antigen complex without a co-stimulatory signal, to result in a non-active T cell and 
subsequent tolerance of the tumor, as seen with engagement of CTLA-4 or PD-1 (145). 
Particularly, indoleamine-2,3-dioxgenase or IDO, has been reported to cause T-cell anergy (146). 
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Of importance, IDO is upregulated in high-grade glioma and correlates with a poor prognosis (18, 
23).  In the setting of cancer immunology, the catabolism of tryptophan by IDO is sensed by the 
surrounding T cells, eliciting stress responses to prompt cell cycle arrest (146, 147) and decreases 
in proliferation (148). Furthermore, the metabolites of tryptophan, including kynurenine, can 
induce apoptosis of effector T-cells and its differentiation into immunosuppressive regulatory T 
cells through activation of the aryl hydrocarbon receptor (AhR) (32, 33, 149-151). Activation of 
AhR also stimulates dioxin responsive elements that aid in transcription of carcinogenic 
mediators.  Furthermore, AhR activates immunosuppressive macrophages, and other populations 
of cells causing immunosuppression (46). Of relevance to our study, IDO expression increases 
dramatically after virus infection and is inducible by IFNү (63, 152), which is a direct effect of 
adenoviral infection. Moreover, the use of IDO inhibitors has been seen to reverse immune 
resistance in IDO-expressing tumors (18). Collectively, these data suggest the 
immunosuppression by IDO and the activity of a continual feedback loop of IDO during a viral 
infection, providing the rationale to target IDO in combination with the treatment of the Delta-
24-RGDOX. In summary, a functional IDO can cause immunosuppression within the tumor 
microenvironment and thus decrease the immune effects of oncolytic viruses. Based on these 
observations, the central hypothesis of this study is that therapy of Delta-24-RGDOX combined 
with an IDO inhibitor will stimulate a cytotoxic immune response and inhibit the suppressive 
immune response against the tumor cells providing a potential effective novel treatment for 
glioblastoma. Figure 1 shows the current working model of our proposed hypothesis.  
To test the central hypothesis and achieve the objectives of the project, we proposed the following 
two specific aims: 
Aim 1: Compare the therapeutic efficacy of using Delta-24-RGDOX with and without 
IDO inhibitors in mouse models of glioblastoma. 
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Aim 2: Analyze the ability and effectiveness of Delta-24-RGDOX in combination with IDO 
inhibitors to reshape the murine glioblastoma microenvironment. 
Accomplishing the aims of this project will provide valuable information about the effects of 
manipulating several axes of the immune system to achieve an anti-tumor immune response and 
will elucidate the role of immunomodulators and IDO in T-cell anergy during active virotherapy. 
These results should provide the basis for the future translation of the proposed strategy to the 




Figure 1: The current working model of our proposed hypothesis. 
Infection of the glioblastoma cell by Delta-24-RGDOX can increase the expression and activation 
of IDO via IFN responses. The subsequent activation of IDO catabolizes tryptophan (L-Trp) into 
kynurenine (Kyn). Kyn acts as an activating ligand for the carcinogenic transcription factor, aryl 
hydrocarbon receptor (AhR). Activation of AhR by Kyn will translocate it to the nucleus and 
promote stimulation of dioxin responsive elements (DRE), which aid in transcription of target 
genes of the glioblastoma cell that will result in carcinogenesis and immunosuppression. 
Activation of the IDO-Kyn-AhR pathway in immune cells can decrease proliferation and 
function, limiting the immune response against cancer cells. Overall, the effect of infection of 
glioblastoma by Delta-24-RGDOX will produce an immunosuppressive microenvironment via 





Chapter 2: Materials and Methods 
 
Cell Lines 
Mouse glioma cell lines, GL261, GL261-5 (GL261 isolated clone with slower in vivo 
growth kinetics than parental cells) (91), or GL261-IDO-OE (the GL261 cell line with constitutive 
IDO overexpression, kindly provided by Dr. Derek Wainwright of Northwestern University, 
Feinberg School of Medicine) were cultured in Dulbecco’s modified Eagle’s medium with 
nutrient mixture F12 (DMEM/F12). Mouse GSC-005 cells (kindly provided by Dr. Inder M 
Verma of the The Salk Institute for Biological Studies) were maintained in DMEM/F12 
supplemented with N2 (1x, Invitrogen), fibroblast growth factor-2 (20 ng/mL, PeproTech), 
epidermal growth factor (20 ng/mL, Promega), and heparin (50 μg/mL, Sigma). Mouse melanoma 
cell line B16-F10 and mouse breast cancer cell line 4T1.2 cells expressing the luciferase gene 
(kindly provided by Dr. Chandra Bartholomeusz of the University of Texas MD Anderson Cancer 
Center) were both maintained in RPMI 1640 medium.  Human HeLa and HEK293 cells were 
maintained in DMEM, and human A549 cells were maintained in DMEM/F12. Human neuronal 
or glioma stem cell (NSC or GSC) lines NSC11, GSC20, GSC7-2, GSC13, and GSC8-11 were 
cultured in DMEM/F12 with B27 (1x, Invitrogen), antibiotic-antimitotic (1x, ThermoFisher 
Scientific), basic fibroblast growth factor (20 ng/mL, Sigma), and epidermal growth factor (20 
ng/mL, Sigma). Cultures, except for cultures of GSCs, were supplemented with 10% fetal bovine 
serum (HyClone Laboratories) and antibiotics (100 μg/mL penicillin; 100 μg/mL streptomycin) 








Two previously constructed oncolytic adenoviruses, Delta-24-RGD (80) and Delta-24-
RGDOX (91), were propagated in human lung carcinoma A549 cells. Virions were collected and 
purified using the Adenopure kit (Puresyn, Inc, Malvern, PA) following the manufacturer’s 
instructions.   Viral titers and replication were determined by measuring plaque-forming units per 
mL (pfu/mL), by conventional methods. Briefly, HEK293 (2.5 x 105) cells were incubated in 24-
well plates with serial dilutions of the viral stock. Forty-eight hours later, cultures were fixed with 
100% ice-cold methanol for 10 min at -20°C. Cells were stained for hexon expression using an 
anti-adenovirus polyclonal antibody (1 h, 37˚C) (anti-adenovirus, Millipore Sigma, AB1056), 
followed by secondary staining with a biotinylated anti-goat IgG (1 h, 37˚C) (Biotinylated anti-
goat IgG (H+L), Vector Biolabs, BA-5000). The Vector Vectastain ABC kit (PK-4000) and 
ImmPACT DAB peroxidase substrate kit (SK-4105) was utilized for visualization of positive 
cells. Hexon-stained areas were counted under a light microscope (20× objective) in 10 individual 
fields per well. In wells with viral dilutions showing 5-50 positive cells/field, the viral titer was 
calculated using the following formula: pfu/mL = [(mean number of positive cells/field) * 
(fields/well)] / [volume virus (mL) * dilution factor]. 
 
IDO Inhibitors 
For mice treated with IDO inhibitors, the following reagents were administered: 
Indoximod or 1-methyl-DL-tryptophan (1MT) (both purchased from Sigma-Aldrich) suspended 
in PBS containing glass balls (3mm, Thomas Scientific, #3000) and rotated overnight to help re-
suspend the drug to form a uniform and smooth solution. We also used a clinical grade direct 
enzyme inhibitor called BGB-7204 (kindly provided by Dr. Derek Wainwright of Northwestern 
University, Feinberg School of Medicine), which was suspended in Ora-Plus (Oral Suspending 
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Vehicle from Perrigo), and whose pharmacokinetic/pharmacodynamics properties were 
previously described (57). For in vitro use of these inhibitors, DMSO was used as the diluent, and 
stored at -80°C in between uses.  
 
In Vivo Studies 
For glioma tumor implantations, 5 × 104 GL261-5 or GSC-005 cells/mouse or 1 × 103  
B16-F10 cells/mouse were implanted into the caudate nucleus of 7- to 10-week-old male or 
female C57BL/6 mice by using a guide-screw system as previously described (84), and then mice 
were randomly assigned to experimental groups. Treatment began 7 days after tumor cell 
implantation. Delta-24-RGDOX adenoviruses (5 × 107, 2.5 × 107, 1.25 × 107, or 1 × 108 pfu/dose, 
depending on the study) were injected intratumorally on days 7, 9, and 11. For 4T1.2 breast cancer 
tumor implantation, 1 × 104 cells were injected into the right mammary pad of 7-to 10-week-old 
female BALB/c mice; intratumoral Delta-24-RGDOX injections were administered on days 10, 
14, 16, 18, and 21. Indoximod (275 mg/kg), 1MT (400 mg/kg), or BGB-7204 (100mg/kg) was 
administered twice daily, by oral gavage, 5 days/week, for 28 days. Mice surviving 120 days were 
re-challenged with a new intracranial tumor injection using GL261-5 cells (5 × 104 cells/mouse) 
on the contralateral side of the initial tumor injection. For the CD4 depletion experiment, anti-
CD4 depletion antibodies (200 µg per dose, clone GK1.5, InVivoMAb, BioXcell) and rat IgG2b 
isotype control (anti-keyhole limpet hemocyanin, 200 µg per dose, InVivoMAb, BioXcell) were 
administered intraperitoneally in mice starting on day 4 post tumor implantation and continued 
every fourth day until day 36.  C57BL/6 IDO-KO (B6.129-Ido1tm1Alm/J ) mice were purchased by 
The Jackson Laboratory, and bred in our mouse housing facility. All experimental procedures 
involving mice were performed in accordance with protocols approved by the Institutional Animal 
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Care and Use Committee of MD Anderson Cancer Center, National Institutes of Health, and 
United States Department of Agriculture guidelines.  
 
RNA-sequencing and data analysis  
Total RNA was extracted from flash frozen tumor using the RNeasy Plus Mini Kit 
(Qiagen). Sequencing was performed by Novogene. Quality control of RNA was performed to 
measure quantification using Nanodrop, test RNA degradation or potential contamination using 
agarose gel electrophoresis, and check for RNA integrity using Agilent 2100 Bioanalyzer System. 
Library construction was developed from mRNA eukaryotic organisms, which was enriched using 
oligo(dT) beads. This eukaryotic mRNA is then fragmented randomly in fragmentation buffer, 
followed by cDNA synthesis using random hexamers and reverse transcriptase. After first-strand 
synthesis, a custom second-strand synthesis buffer (Illumina) is added with dNTPs, RNase H, and 
Escherichia coli polymerase I to generate the second strand by nick-translation. The final cDNA 
library is ready after a round of purification, terminal repair, A-tailing, ligation of sequencing 
adapters, size selection, and PCR enrichment. Sequencing was performed using HiSeq machines 
(Illumina). Key steps of RNA-seq data analysis include evaluation of quality of reads by fastqc 
(fastqc/0.11.8) followed by removal sequencing adapters and unpaired reads by trimmomatic 
(trimmomatic/0.33). (153) These trimmed FASTQ files were used to map reads to mouse genome 
/ENSEMBL.mus_musculus.release-75 by STAR aligner (star/2.6.0b) (154). Feature Counts 
extracted from resulting .bam files by subread (subread/1.6.3) (155). Estimates of unwanted 
variations in raw read counts across samples were determined by ‘remove unwanted variation’ on 
Galaxy platform (RUVs: which estimates the factors of unwanted variation using replicate 
samples) (156). RUV uses the empirical Bayes approach to estimate a moderated t-statistic. These 
estimates were used as batch factors in DESeq2 analyses to determine differentially expressed 
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genes in the group comparisons (157). For preparation of heatmaps, log2 normalized values for 
genes with significant adjusted p-value (<0.05) from DESeq2 analyses was utilized; both rows 
and columns were hierarchically clustered using one minus pearson correlation with average 
linkage. For gene ontology (GO) enrichment analysis, log2(FC) values for genes with significant 
adjusted p-value (<0.05) from DESeq2 PBS vs. RGDOX analyses; enrichment analyses were 
performed on http://www.pantherdb.org/, with false discovery rate (FDR) correction. Cutoffs for 
ingenuity pathway analyses (IPA), were p-value ≤0.05 and log2(FC) = ±1; activation z-score are 
plotted on graphs. Activation z-score of ±2 was considered significant. Expression levels of genes 
with significant fold change and p-values in PBS vs RGDOX analysis were overlayed onto IDO1 
network (curated from IPA’s knowledge base). For the prediction of immune cell compositions 
as inferred from RNA-seq data, we input transcripts per million (TPM) for each sample to seq-
ImmuCC platform (158), the predicted percentages of various immune cell populations in each 
sample were plotted in excel. The gene set enrichment analyses were performed by utilizing 
GSEA_4.0.3 software, where whole genome expression profiles of PBS and Delta-24-RGDOX 
treated tumors were used as input. The Treg gene set was curated from IPA’s knowledge base and 
the MSDC gene set was based on previous publication (159). 
 
Viral Replication Assay 
To determine the replication ability of Delta-24-RGDOX in the cell lines used in this study 
we performed the viral replication assay. For adherent cells, we seeded 1.5 x 105 cells/well in a 
12 well plate, then counted the cells after letting them attach overnight to calculate the appropriate 
amount of Delta-24-RGDOX needed to achieve specified multiplicities of infection (MOI). Delta-
24-RGDOX was diluted in PBS to achieve the certain MOI and added dropwise to the attached 
cells in 200 µL of serum free media for 20 min at 37˚C and shaken to disperse the virus every 5 
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min, after which was replaced with 1 mL of complete medium for 48 h. For non-adherent cells, 
infection occurred in 200 µL of serum free media for 20 min at 37˚C and shaken to disperse the 
virus every 5 min, after which, 800 µL of complete medium was added for 48 h. After the 48 h 
incubation period, cells and supernatant were collected, flash frozen and thawed 3x, then 
centrifuged at 500g for 5 min. The supernatant was used for viral titration in 293 cells, as 
explained in the “Oncolytic Adenoviruses” section in methods.  
 
Viral-Induced Cytopathic Ability of Virus Assay  
To determine the viral-induced cytopathic ability Delta-24-RGDOX in the cell lines used 
in this study, we seeded 1 x 104 cells/well in a 96 well plate at 75 µL. An additional 75 µL was 
added to the cells containing the appropriate treatment. Viral-induced cytopathic ability was 
measured every 24 h for up to 168 h, via levels of ATP using the ViralToxGlo Assay (Promega) 
according to the manufacturer’s protocol.  
 
AhR Activity Assay 
To assess the activity of AhR by Delta-24-RGDOX, cells were uninfected or infected with 
50 MOI of Delta-24-RGDOX and incubated for 48 h; cell supernatants were used in a 
commercially available Human Aryl Hydrocarbon Receptor (AhR) assay kit (INDIGO 
Biosciences), which uses AhR Reporter Cells that give off a luminescent signal when AhR is 
activated. The protocol was performed according to the manufacturer instructions. 
 
AhR Immunofluorescence 
HeLa cells were seeded in a 96-well clear bottom black sides tissue culture plate (Corning) 
at a density of 1 x 104 cells per well. Cells were uninfected (mock), treated with 150µM of Kyn, 
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or infected with 25 MOI of Delta-24-RGDOX in complete media for 48 h. Following treatment, 
immunofluorescence staining was performed by following the procedures provided by the 
manufacturer of the primary antibody. Briefly, cells were washed with PBS and fixed with 4% 
formaldehyde in PBS for 10 minutes at RT. After washing the wells three times with wash buffer 
(2mg/ml BSA in PBS), cells were permeabilized with 0.2% triton X-100 in wash buffer for 30 
minutes at RT in moist chamber. After permeabilization, cells were washed three times with wash 
buffer and overlaid with primary antibody against AhR (SantaCruz, SC-74572) using a 1:100 
dilution in 2mg/ml BSA in PBS overnight. After primary antibody incubation, cells were washed 
three times with wash buffer and incubated with FITC conjugated secondary antibody (Invitrogen, 
Alexa Fluor 488 Goat anti Mouse, A11001) at 1:100 dilution for 1 h at RT. Cells were washed 
four times with wash buffer and then stained for DAPI (1µg/ml). Cells were then overlaid with 
mounting medium and imaged using a Zeiss Axiovert200. Cellular and nuclear quantification of 
AhR intensities was performed using ImageJ software. 
  
Quantitative Real-Time Polymerase Chain Reaction 
To isolate mRNA from cultured cells, Trizol Reagent was used according to the 
established routine protocol; to isolate mRNA from freshly dissected tissue samples, the RNeasy 
Plus Mini Kit (Qiagen) was used. One microgram of total RNA was reverse-transcribed into 
mRNA using the High Capacity RNA-to-cDNA Kit (Applied Biosystems). Quantitative real-time 
polymerase chain reaction (qRT-PCR) was performed on the 7500 Fast Real-Time PCR System 
(Applied Biosystems) using SYBR Green PCR Master Mix (Applied Biosystems). Primers were 
purchased from Sigma Aldrich (human IDO, R: TGGAGGAACTGAGCAGCAT, F: 
TTCAGTGCTTTGACGTCCTG; mouse IDO, R: TTGCGGGGCAGCACCTTTCG, F: 
CCCACACTGAGCACGGACGG). The RT-PCRs were conducted in a 96 well plate and 
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subjected to a 10 min 95˚C holding stage followed by 40 cycles of 30 sec at 95˚C, 30 sec at 60˚C 
and, 45 sec of 72˚C, followed by an infinite hold at 4˚C. Relative gene expression was calculated 
using the 2−ΔΔCt method by normalizing the threshold cycle (Ct) values of the gene of interest to 
the Ct values of the internal housekeeping gene.  
 
Western Blots  
To detect protein expression, cell lysates were prepared using RIPA lysis buffer (20mM 
HEPES pH 7.0, 200mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 5mM sodium 
pyrophosphate, 80mM β-glycerophosphate, 50mM NaF, 0.1% SDS) plus freshly added protease 
inhibitor cocktail (1x, Sigma-Aldrich), proteasome inhibitor (MG-132, 1µM, Calbiochem), and 
phosphatase inhibitor cocktail 3 (2.5mg/ml, Sigma-Aldrich). Cell lysates were flash frozen in 
liquid nitrogen 3x, and centrifuged for 10 min at 4C, 13,000 rpm. Supernatants were collected, 
and the concentration of protein was measured using the Bradford Protein reagent (Bio-Rad, 
Hercules, CA). DTT (50 mM) and NuPAGE LDS sample buffer (ThermoFisher) were added to 
10-15 g of total protein. After heated at 95C for 5 min, samples were run on 4-20% Novex Tris-
Glycine gels (Invitrogen), and then transferred to a PVDF membrane (ThermoFisher) and probed 
with primary antibodies overnight at 4°C (Table 1 shows antibodies and working dilutions), 
followed by 1hr secondary antibody staining at RT the next day. Protein bands were visualized 
using Western Lightning Plus-ECL, Enhanced Chemiluminescence Substrate (Perkin Elmer). 
Images were acquired using the ChemiDoc System (Bio-Rad). 
 
Liquid Chromatography- Mass Spectrometry (LC-MS) 
To detect IDO activity, we measured kynurenine and tryptophan levels of differently 
treated flash frozen brain tumors. Liquid Extraction was used for the extraction of polar 
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metabolites from the frozen brain tissue. Briefly, 400 µL of 80% methanol was added to the frozen 
tissue. Zirconia/silica beads (1mm diameter) were added to the tube. The tissue was broken down 
using a bead beater by pulsing the tissue for 45 seconds.  The resulting solution was kept on ice 
for 30 min to precipitate out the proteins. 400 µL of chloroform was added and the tube pulsed in 
the bead beater for additional 45 sec and kept in ice for 15 min. 200 µL of water was added to 
induce phase separation. The tube was centrifuged and the upper aqueous phase containing the 
amino acids/amines was carefully transferred into another tube. 250 µL of the 500 µL aqueous 
phase was dried under using a vacuum. The dried tube containing the metabolites was resuspended 
in 40µL of buffer used for the derivatization of the amino acids/amines. 10 µL of this was taken 
for further derivatization and analysis by LC-MS. Standard calibration curves of known 
concentration of amino acids including tryptophan and kynurenine were made. Before analysis 
by LC-MS, 5 µM of stable isotope labeled amino acids including tryptophan and kynurenine in 
10 µL are added to each sample. The concentration in the analysis sample is then calculated using 
linear regression on the standard concentrations by plotting area ratio (ratio of the peak area of 
analyte to peak area of the internal standard) and the known concentrations, followed by 
normalization to tumor mass. 
 
Preparation of Single Cell Suspensions from Murine Brains and Spleens 
Mouse hemispheres bearing tumors and spleens were collected. Initial suspensions were 
obtained by cutting the tissue or grinding the organs and filtered through 100-μm cell strainers 
(Fisher Scientific), then placing the cell suspension in RPMI 1640 medium (10 mL/sample). All 
tissues were pelleted by centrifugation (500 × g for 7 min at RT). The spleen-derived pellet was 
re-suspended in Red Blood Cell Lysing Buffer Hybri-Max (Sigma-Aldrich) to lyse the red blood 
cells, according to the manufacturer’s instructions. Then, the cell suspension containing the Red 
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Blood Cell Lysing Buffer was brought up to 20 mL/sample with RPMI 1640 medium to stop the 
lysis reaction, and the cells were washed 1x in PBS. For the brain-derived pellet, 1 wash in HBSS 
(Corning) was performed, followed by incubation of cells in 8 pg/mL of Liberase TM (Millipore 
Sigma) and another wash in HBSS, then resuspended in 40% percoll (1.130 g/mL; GE 
Healthcare), which was overlaid on top of 80% percoll at a 1:1 ratio. The cells were centrifuged 
for 20 min at 500 × g at RT with an acceleration of 1 and a deceleration of zero, and the 
lymphocyte gradient interphase was collected and washed once with PBS. The cells from the 
brains and spleens were pelleted by centrifugation at 500 × g for 7 min at RT and finally re-
suspended in FACS buffer (1x PBS containing 10 mM HEPES, 2 mM EDTA, and 1% fetal bovine 
serum).  
 
Flow Cytometry Analysis  
To analyze cell surface protein expression, using a 96-round bottom plate, single cell 
suspensions from murine brains and spleens were first blocked in Anti-Mouse CD16/CD32 Fc 
Block (eBioscience; 14-0161-85) diluted with FACS buffer and then washed once with 250 µL 
of cold PBS. The cells were then incubated in 100 µL of diluted viability dye (please see Table 1 
for details) at 4°C in the dark for 30 min and then washed once with 250 µL of cold PBS. Then, 
the cells were incubated in 100 μL of primary antibody solution diluted in FACS buffer. After 
incubation at 4°C in the dark for 30 min, the cells were washed once with 250 µL of cold PBS. 
For analysis of intracellular proteins, cells were stained with the eBioscience 
FOXP3/Transcription Factor Staining Buffer Set (Invitrogen) following the manufacturer’s 
instructions. The cells were finally re-suspended in 0.3 mL of FACS buffer containing 123count 
eBeads Counting Beads (Invtirogen), to acquire an accurate output for absolute cell count. The 
stained cells were then analyzed by using the BD Celesta Flow Cytometer (BD Biosciences). 
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FlowJo software, version 10 (FlowJo, LLC), was used for the analysis. (Table 1 shows the 
antibodies and working conditions used.) To control for the technique and to arrange population 
gates accurately, we generated fluorescence minus one (FMO) samples for each antibody using 
pooled spleen cells from the differently treated brain tumor bearing mice.  
 
Analysis of Stimulation of Splenocytes in Co-Cultures with Target Cells 
Co-culture set up 
Indicated target cells were seeded and treated with specified treatment. Four hours later, 
100 units/mL of mouse interferon gamma (IFNγ) (ProSpec Protein Specialists) were added to the 
cultures. Forty-eight hours after viral infection, the cells were detached with 2 mM EDTA in PBS, 
fixed with 1% paraformaldehyde, and cleaned with lysine (0.1 M) wash solution. A total of 2 × 
104 fixed cells were seeded in 96-well round-bottom dishes. To activate immune cells, pre-fixed 
target cells were co-cultured with splenocytes (5 × 105/well) in RPMI 1640 medium containing 
100 μg/mL penicillin (Corning), 100 μg/mL streptomycin (Corning), and 55 µM beta-
mercaptoethanol (Gibco) for 48 h.  Please refer to section “Preparation of Single Cell 
Suspensions from Murine Brains and Spleens” for description of how splenocytes were 
processed into single cells.  
IFNγ or IL-2 ELISA 
For analysis of stimulation of splenocytes in co-cultures with target cells, the 
concentration of IFN or interleukin-2 (IL-2) in the supernatant was assessed with a standard 







Mouse brains bearing tumors were fixed in 10% buffered formalin for 24 h, transferred to 
70% ethanol, and then embedded in paraffin for slide sectioning. Paraffin-embedded sections of 
the mouse brain tumors were deparaffinized at 60°C for 1 h and rehydrated with xylene and 
ethanol following conventional procedures. For hematoxylin and eosin staining, brain tumor 
sections were stained with Harris hematoxylin (Fisher Scientific) and Eosin-Y solution (Fisher 
Scientific) and mounted with Cytoseal 60 (Thermo Scientific). For the CD3 
immunohistochemistry, antigens were retrieved from the brain tumor sections by exposing the 
slides to 10 mM citric acid (pH 6.0) inside a steamer for 30 min. Slides were then incubated in 
3% hydrogen peroxide in 100% methanol for 10 min at RT to quench endogenous peroxidases. 
The sections were then subjected to blocking with 5% goat serum in PBS (1 h at RT), followed 
by incubation in primary rabbit monoclonal anti-CD3 antibody overnight (1:80, Abcam, ab16669) 
and incubation with a biotinylated anti-rabbit IgG secondary antibody diluted in 1% goat serum 
(1:200, Vector, BA-1000). The Vector Vectastain ABC kit (PK-4000) and ImmPACT and DAB 
Peroxidase Substrate Kit (SK-4105-Reagent 1) were utilized to visualize positive cells. Images 
were captured using the Aperio ScanScope slide scanner. The Aperio ScanScope slide scanner 
was also used to measure high grade tumor areas.  
 
Statistical analyses 
In quantitative studies, each tested group were performed at least in triplicate. All graphs 
and statistical tests of in vitro and in vivo studies were generated using GraphPad Prism 9. Column 
data graphs are presented as mean ± standard deviation. To determine statistical differences of 
multiple groups, we performed an ordinary one-way ANOVA. To determine statistical differences 
of two groups, we performed a 2-tailed Student’s t-test, or the Tukey’s multiple comparisons test 
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(which can be derived via the ordinary one-way ANOVA by selecting the option that compares 
every mean with every other mean). P values < 0.05 were considered significant. 
Statistical consideration and analyses for our survival studies are based on our preliminary 
data, which indicated that survival in the control mice is roughly normally distributed with a 
median of about 38 days and a standard deviation of about 11 days. The treated mice have a 
standard deviation of about 22 days (since treated mice respond to varying degrees). Unless 
otherwise stated, we used at least 10 mice per group based on computer simulations that 
demonstrated roughly 91% power to detect 30 day differences in median survival between treated 
and control groups (using a two-sided 1% alpha). We used Kaplan-Meier estimates to graph  the  
survival  curves  and  performed  the  Log-rank Mantel-Cox test to  assess  for  differences, where 







Table 1: List of antibodies used in hexon titration, western blot, and flow cytometry 
assays. 
  
Hexon Titration   
Antibody Name Company 
Catalog 
Number 











BA-5000 1:500   
      
Western blot  
Antibody Name Clone Company Catalog Number Dilution  
Fiber: 
Adenovirus 
Type 2 Fiber 
Antibody (4D2) 
4D2 ThermoFisher MA5-11222 1:1000  
Adenovirus-2/5 
E1A Antibody 
M73 Santa Cruz sc-25 1:500  
α Tubulin 
Antibody 
B-5-1-2 Santa Cruz sc-23948 1:2000  
      
Flow Cytometry: Regulatory T-Cell Panel 




CD45 30-F11 APC-R700 BD Biosciences 565478 1:100 
CD3e 145-2C11 PerCP-Cy5.5 BD Biosciences 551163 1:100 
CD4 RM4-5 V450 BD Biosciences 560468 1:100 
CD8 53-6.7 BV510 BD Biosciences 563068 1:100 
CD25 PC61 APC BD Biosciences 557192 1:100 








      
Flow Cytometry: MDSC Panel 




CD45 30-F11 APC-R700 BD Biosciences 565478 1:100 
CD3e 145-2C11 PerCP-Cy5.5 BD Biosciences 551163 1:100 
GR1 RB6-8C5 FITC BD Biosciences 553126 1:100 
CD11b M1/70 APC BD Biosciences 553312 1:100 
FVS780 NA BV780 BD Biosciences 563068 1:1000 
      
40 
 
Chapter 3: Transcriptome analyses of Delta-24-RGDOX shows activation of IDO-related genes 
and the triggering of immune activation and pro-inflammatory pathways.  
 
Rationale and Expectations 
A recent phase I study showed that the treatment of recurrent glioblastoma patients with 
Delta-24-RGD resulted in about 20% of patients living past three years (90). Furthermore, the 
exploratory objectives of this study showed that in addition to the anti-tumor effect of Delta-24-
RGD, a robust immune response was also elicited. This was evident in the H&E sections that 
showed infiltration of immune cells within the tumor. Furthermore, immunohistochemical 
analysis also showed infiltration of T-bet associated CD8+ T cells within the Delta-24-RGD 
infected brain tumor, suggesting the Delta-24-RGD mediated activation of a Th1 mediated 
immune response (90). 
With the goal of improving the percentage of patients that respond to Delta-24-RGD, we 
developed the next generation virus called Delta-24-RGDOX, which contains the cDNA of 
immune agonist, OX40L (91).  In addition to eliciting oncolysis, Delta-24-RGDOX can also 
express OX40L on the tumor cell surface (91), enhancing the co-stimulation signal of activated T 
cells to increase the number of clones that are activated within the tumor microenvironment (93).  
The treatment of tumors with Delta-24-RGDOX should be able to stimulate both anti-viral 
responses and increase the immune activating arm via the OX40L-OX40 pathway. Thus, we 
hypothesized that Delta-24-RGDOX can dramatically reshape the microenvironment.  
To test our hypothesis, we performed RNA sequencing analyses on GL261-5 mouse brain 
tumors that were treated with PBS or Delta-24-RGDOX. To determine global gene expression 
changes between the two groups, we generated a heat map of all differentially expressed genes. 
Furthermore, we performed enrichment analyses of gene ontology biological processes to 
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determine the differences between the untreated and Delta-24-RGDOX treated brain tumors. 
Moreover, we performed ingenuity pathway analyses to determine the top five canonical and 
upstream regulator pathways that were upregulated in response to Delta-24-RGDOX. Additional 
analyses also determined the prediction of immune cell composition within the untreated and 
treated brain tumors. Lastly, we explored the expression pattern of the IDO pathway.  
Based on previous studies showing that Delta-24-RGDOX was more effective in 
generating immune responses and curing murine GL261-5 brain tumor bearing mice (91), we 
expected that in response to Delta-24-RGDOX, the Gl261-5 brain tumors would be dramatically 
different compared to untreated brain tumors in terms of their global gene expression. 
Furthermore, we expected that Delta-24-RGDOX would increase the immune responses, based 
on our hypothesis that treatment of the tumors with the adenovirus will increase the 
immunogenicity of the tumors (41). As such, we expected both immune activating and immune 
suppressing pathways, including the IDO pathway, to increase in Delta-24-RGDOX treated brain 





Because RNA-seq allows an unbiased cellular and molecular profiling of complex tissues 
in solid tumors, characterized by phenotypic alterations due the multicellular composition of the 
cancer cells and the tumor microenvironment, we decided to perform RNA-sequencing analyses 
of murine glioma tumors infected with Delta-24-RGDOX and control-treated tumors.  
 
Delta-24-RGDOX reshapes the murine brain tumor microenvironment.  
We observed that Delta-24-RGDOX treatment induced a powerful reshaping of the tumor 
microenvironment (Figure 2). In comparison with control-treated tumors, Delta-24-RGDOX-
treated tumors were enriched for populations related with inflammation and Th1 and Th17 
immune response, including IFNγ, TNF, and IL-17 (Figure 3).  
 
Delta-24-RGDOX increases the predicted diversity and percentage of immune populations. 
While transcriptional signatures related to macrophages and dendritic cells remain 
practically unchanged by the Delta-24-RGDOX treatment, major changes in the 
microenvironment promoted by the infection included the remarkable increase of the CD8+ T 
related transcriptome (P = 0.0031), which were practically absent in the control treated tumors, 
and a trending in the upregulation of the NK transcriptional signature (P = 0.11). In addition, there 
was a significant decrease in the predicted presence of CD4+ T cells (P = 0.0127) (Figure 4).  
 
Delta-24-RGDOX induces expression of genes from the IDO pathway. 
As expected, after viral infection, the tumors showed upregulation of the IDO circuitry, a 
pathway targeted for virus and tumors to escape the immune system. IDO-related network of 
genes that were upregulated after Delta-24-RGDOX treatment included TGFβ, CTLA-4, PD-1, 





Figure 2: Delta-24-RGDOX reshapes the brain tumor microenvironment.  
Differentially expressed genes in tumors treated with PBS versus tumors treated with 
Delta-24-RGDOX are utilized for clustering or GO biological process. A) Heatmap 
comparing the transcription signature of intracranial GL261-5-derived tumors treated with 
PBS or Delta-24-RGDOX. The log2 normalized expression levels of genes with 
significant adjusted P-value (<0.05) across samples are shown. Color scale is shown on 
top of the heatmap. (B) Gene ontology (GO) biological process enrichment in tumors 
treated with PBS or Delta-24-RGDOX. The five most significant (±) GO biological 
processes are represented. GO biological processes significantly associated with PBS 








Figure 3: Delta-24-RGDOX increases both immune-activating and immune-suppressing 
pathways.  
Ingenuity pathway analyses of GL261-5 brain tumors treated with PBS or Delta-24-RGDOX. 
(A) Five most significantly altered canonical pathways in tumors treated with PBS versus 
Delta-24-RGDOX. Activation z-score are plotted in the graph. (B) Five most significantly 
altered upstream regulators in tumors treated with PBS versus Delta-24-RGDOX. Activation 
z-score are plotted in the graph. The –ve z-Score represent activation in Delta-24-RGDOX. †, 
Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza; ††, 




Figure 4: Delta-24-RGDOX increases and diversifies the predicted immune cell 
composition within the brain tumor microenvironment. 
(A) The prediction of immune cell composition in GL261-5-derived brain tumors treated with 
PBS or Delta-24-RGDOX. The percentages of various immune cell populations in each sample 
are presented in the graph. The color code for various immune cell types is shown on the right 





Figure 5: Delta-24-RGDOX induces expression of genes from the IDO pathway.  
A) IDO1 network genes with significantly altered expression levels in tumor treated with PBS 
or Delta-24-RGDOX. The intensity of color depicts log2 fold change levels for each gene in 




Collectively, these results indicated that Delta-24-RGDOX induces a robust effect on the 
immune response and that there was a double-edge activation of pathways that positively and 
negatively regulate the immune response against virus and tumors. Among them, the infection 
with Delta-24-RGDOX triggered the upregulation of the IDO circuitry. 
Importantly, this data shows that the treatment of these murine brain tumors increases the 
immunogenicity of the tumors, as indicated by the gene ontology biological processes analyses, 
which showed the enrichment of cancer cell cycles pathways in the PBS treated tumors and the 
contrasted enrichment of immune-related pathways in the Delta-24-RGDOX treated brain tumors. 
Furthermore, the prediction of the immune cell composition also suggests that Delta-24-RGDOX 
increases the diversity of various immune populations. Similarly, the ingenuity pathways analyses 
showed the elicitation of immune pathways. In addition to this increase of immunogenicity, it is 
noteworthy to mention that Delta-24-RGDOX does not only elicit immune activating pathways, 
but also immune suppressing pathways, including the IDO pathway.  
These results confirm our hypothesis that oncolytic adenoviruses can transform “cold” 
tumors to “hot” tumors. This phenomenon was elegantly described by Sharma and Allison, which 
states that this conversion of immunogenicity can increase the likelihood of tumors to respond to 
immunotherapies (41). Complimentarily, the upregulation of the IDO pathway support our 




Chapter 4: IFNγ or Delta-24-RGDOX infection induces IDO or AhR expression or activation 
in vivo and in vitro in human glioma stem cells and murine glioma cells. 
 
Rationale and Expectations 
Indoleamine-2,3-dioxygenase (IDO) is upregulated in glioblastoma and correlates with a 
poor prognosis (23). IDO is an enzyme that catabolizes tryptophan (Trp) into kynurenine (Kyn). 
The production of Kyn causes immune toxicity of the tumor microenvironment. Kyn also acts as 
a ligand to activate aryl hydrocarbon receptor (AhR) translocation into the nucleus, which can 
elicit carcinogenesis and further immune suppression (27, 29). In the context of oncolytic 
virotherapy, tryptophan depletion by IDO activation can hinder the generation of new virions, 
reducing viral spread. IDO is inducible by stimuli that are related to viral infection (58), which 
means that upon infection, generation of a positive IDO-Kyn-AhR pathway feedback loop can 
occur that aids in decreased viral activity.  
Several studies have identified IDO activation during the response to external-danger 
stimuli, including pathogens, like viruses (27, 58, 160). Following viral infection, the main players 
involved in IDO activation are pathogen-associated molecular patterns, damage-associated 
molecular patterns, and the activation of interferons, all of which are important for the innate and 
adaptive responses (27). Studies have shown that human immunodeficiency virus and influenza 
infections induce IFNγ production (59, 66). Furthermore, one study found that HIV infection of 
PBMCs in vitro leads to secretion of type I interferons, IFNα and IFNβ (61). Importantly, these 
studies show that these interferons effect IDO expression and activation. Relatedly, reports have 
shown that in addition to generation of pathogen associated molecular patterns, adenoviral 
infections lead to type I and type II IFN responses, including IFNα or IFNβ, and IFNγ, 
respectively (69-72). Important to our studies, IDO is an IFN-inducible protein (152).  
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An important result of IFNα and IFNβ is its activation of the Janus family kinase-signal 
transducer and activator of transcription (JAK-STAT) signaling cascade. The activation of the 
JAK-STAT elicits host antiviral properties (161). In fact, the use of JAK1/2 inhibitor, Ruxolitinib, 
can enhance replication in a measles virus-resistant human derived glioblastoma cell line (162). 
JAK/STAT activation can also regulate IDO, and several studies have shown that inhibition of 
the JAK-STAT pathway led to inhibition of IDO (reviewed in (163)). Thus, not only can IDO be 
activated directly by IFN, but also via JAK-STAT signaling.  
In summary, IDO is upregulated in glioblastoma and associates with a poor prognosis. 
Furthermore, viral infection elicits several stimuli that are activators of IDO including, IFNα, 
IFNβ, IFNγ, and JAK/STAT. This interplay between viral infection and IDO activation can 
generate a positive feedback loop of the IDO pathway that can: 1) hinder viral replication and 2) 
elicit mechanisms of immune suppression in oncolytic virus treated cancers.  
We wanted to determine the effects of IFNγ and Delta-24-RGDOX in human and murine 
glioblastoma cancer on IDO or AhR expression and activation in vivo and in vitro. Taking into 
consideration the previously published literature of stimuli that lead to IDO and AhR activation, 
we expected the following to occur in the cancer cells: 
1) IFNγ will induce IDO expression. 
2) Delta-24-RGDOX will induce IDO expression. 
3) Delta-24-RGDOX will activate IDO via increased Kyn/Trp levels. 
4) Delta-24-RGDOX will induce AhR expression. 
5) Delta-24-RGDOX will activate AhR.  





IFNγ induces IDO expression in human cancer cells. 
IDO was the first known gene to be inducible by IFNγ (152). Because adenoviruses can 
elicit an IFNγ response in vivo, we wanted to determine the effects of IFNγ on IDO expression in 
a panel of human glioma stem cells (GSC) including NSC 11, GSC 7-2, and GSC20; we also used 
HeLa cells as positive control. Figure 6 shows a significant increase in IDO mRNA levels in the 
glioma stem cells treated with IFNγ. 
 
Delta-24-RGDOX activates the AhR pathway in human cancer cells.  
IDO is an enzyme that catabolizes Trp to Kyn, which can be aided by type I interferons, 
IFNα and IFNβ.  These IFNs can also be elicited in adenoviral infected cells. In turn, Kyn can 
bind to transcription factor AhR to activate it, which has been shown to cause pro-tumorigenic 
effects. (27, 42, 164, 165) Thus, we wanted to explore the activity of AhR in Delta-24-RGDOX 
infected GSCs and HeLa cells; in Figure 7, we showed that there was an increase AhR activity 
in NSC 11, GSC 7-2, GSC20, and HeLa cells in response to Delta-24-RGDOX infection.  
 
Delta-24-RGDOX induces Ahr expression and translocation into the nucleus.  
To further explore the activation of IDO by Delta-24-RGDOX, we studied the expression 
of AhR in HeLa cells that were infected with Delta-24-RGDOX using immunofluorescence. 
Figure 8A shows that Delta-24-RGDOX infected HeLa cells show an observable increase in AhR 
expression within both the cytoplasm and nucleus compared to mock infected cells, indicating the 
translocation of AhR to the nucleus induced by Delta-24-RGDOX. Quantification of these results, 
as seen in Figure 8B-D, showed increase of nuclear AhR intensity, whole cell AhR intensity, and 
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the frequency of AhR positive cells compared to mock treated cells. These data were 
complemented with HeLa cells treated with Kyn, which acted as our positive control. 
 
IFNγ, Delta-24-RGD, or Delta-24-RGDOX induces IDO expression in vitro and in vivo in murine 
models of cancer. 
IDO expression was also inducible by IFNγ or Delta-24-RGDOX in murine glioma cells, 
GL261-5 and GSC-005. When these cell lines were treated with IFNγ or Delta-24-RGDOX, IDO 
mRNA significantly increased compared to mock infected cells, as seen in Figure 9A. To test the 
impact of viral infection on IDO expression in vivo, we treated GL261-5- bearing mice with Delta-
24-RGD or Delta-24-RGDOX and collected their brain tumors 24 h after the last virus dose for 
analysis of IDO expression by qRT-PCR. Figure 9B shows that Delta-24-RGD increased IDO 
mRNA in the GL261-5 model compared to PBS treated mice, and that Delta-24-RGDOX 
increased IDO mRNA expression even further. Furthermore, we showed that Delta-24-RGDOX 
significantly increased IDO mRNA in the murine 4T1.2 breast cancer model, as seen in Figure 
9C, and that IDO expression decreased with the treatment of Trp-mimetic, Indoximod.  
 
Delta-24-RGD or Delta-24-RGDOX induces IDO activation in of murine glioblastoma models. 
Next, we wanted to determine IDO activity in PBS, Delta-24-RGD, or Delta-24-RGDOX 
treated brain tumor bearing mice by measuring the Kyn to Trp ratio by LC-MS. An active IDO 
will catabolize tryptophan and generate an excess of Kyn, therefore a relatively high Kyn to Trp 
ratio indicates IDO activity. As seen in Figure 10, both the GL261-5 and GSC-005 murine brain 
tumor models showed that Delta-24-RGD infection increased IDO activity compared to PBS 
treated mice, as indicated by the increase in the Kyn to Trp ratio. The Kyn to Trp ratio further 





Figure 7: Delta-24-RGDOX activates AhR in human glioma stem cells and HeLa cells.  
The figure shows AhR activity of a human GSC lines and HeLa cells in response to Delta-
24-RGDOX. These cells were untreated (Mock) or infected with 50 MOI of Delta-24-
RGDOX and incubated for 48 hours; the supernatants were used in a commercially available 
Human Aryl Hydrocarbon Receptor (AhR) assay kit (INDIGO Biosciences), which uses AhR 
Reporter Cells that give off a luminescent signal when AhR is activated. Controls included 
media (negative), media containing MeBio (positive), an AhR agonist, and media containing 


















































t-test, p > 0.05 is ns
Figure 6: IFNγ induces IDO expression in human glioma stem cells and HeLa cells.  
Cells were untreated (Mock) or treated with 200 u/mL of IFNγ for 24 hours. RNA was 
extracted and relative levels of IDO was measured using qRT-PCR; GAPDH or β-Actin were 
used as housekeeping gene controls. The column graphs show 2^(CtGAPDH or β-Actin-CtIDO) 























































t-test, p > 0.05 is ns
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Figure 8: Delta-24-RGDOX induces AhR expression and translocation into the nucleus.  
HeLa cells were untreated (Mock), treated with Kyn (positive control), or infected with 25 
MOI of Delta-24-RGDOX, incubated for 48 hours, and then stained with AhR using 
immunofluorescence. The microscopy images (A) show cells stained with Ahr-FITC, DAPI, 
and merged FITC/DAPI. Scale bar, 50 µm. The column graphs represent quantification of 
(B) nuclear AhR intensity, (C) whole cell AhR intensity, and (D) frequency of AhR positive 
cells (analyzed using ImageJ software). 


















































t-test, p > 0.05 is ns
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Figure 9: IFNγ, Delta-24-RGD, or Delta-24-RGDOX induces IDO expression in cancer 
cells in vivo and in vitro.  
Panel (A) shows relative IDO expression murine glioma cells in response to IFNγ or Delta-
24-RGDOX. Cells were untreated (Mock), treated with 200 u/mL of IFNγ, or infected with 
Delta-24-RGDOX for 48 hours at indicated MOIs. RNA was extracted and relative levels of 
IDO was measured using qRT-PCR; GAPDH or β-Actin were used as housekeeping gene 
controls. The column graphs show 2^(CtGAPDH or β-Actin-CtIDO) normalized to the Mock control. 
Panel (B) shows relative IDO expression in GL261-5 brain tumors in response to Delta-24-
RGD or Delta-24-RGDOX infection. Mice were bolted on day -7, then implanted with 5 x 
104 GL261-5 cells on day 0; on days 7, 9, and 11, the mice were intratumorally injected with 
PBS, Delta-24-RGD (5 x 107 pfu/dose), or Delta-24-RGDOX (same dose). Mouse brain 
tumors were collected on day 12, cut in half and flash frozen for RNA extraction. The column 
graph shows relative IDO expression of the differently treated brain tumors using 2^(Ctβ-Actin-
CtIDO) normalized to the PBS treated mice. Panel (C) shows the relative IDO expression of 
4T1.2 bearing mice treated with PBS, Delta-24-RGDOX, or Indoximod. Mice were 
implanted with 1 x 104 4T1.2 cells in the right mammary fat-pad on day 0, injected with PBS 
or Delta-24-RGDOX (1 x 108 pfu/mouse) on days 10, 14, 16, 18, and 21, or treated with 
Indoximod on days 10-35 (275 mg/kg, BID). The 4T1.2 breast tumors were flash frozen on 
day 36 and extracted for RNA and quantified for IDO mRNA using the above methods. 



















































































































































Figure 10: Delta-24-RGD or Delta-24-RGDOX activates the IDO pathway in murine 
gliomas.  
Mice were bolted on day -7, then implanted with 5 x 104 GL261-5 or GSC-005 cells on day 
0; on days 7, 9, and 11 (GL2621-5), or days 9 and 11 (GSC-005), the mice were intracranially 
injected with PBS, Delta-24-RGD (5 x 107 (GL261-5) or 1.25 x 107 (GSC-005) pfu/dose), or 
Delta-24-RGDOX (same doses). Mouse brain tumors were collected on day 12, cut in half 
and flash frozen for analysis of Kyn/Trp by LC-MS. The column graphs are showing (A/B) 
the ratio of Kyn to Trp within the tumor microenvironment of PBS, Delta-24-RGD, or Delta-
24-RGDOX infected brain tumors measured by LC/MS of the (A) GL261-5 or (B) GSC-005 





























































To support previous findings that viral infections generate different stimuli to induce 
expression and activation of IDO and AhR, we performed in vitro and in vivo studies testing 
expression and activation of both proteins induced by IFNγ or Delta-24-RGDOX. 
 We demonstrated that IFNγ induces expression of IDO in human glioma cells and HeLa 
cells. Delta-24-RGDOX induces AhR activation in these same cells. We speculate that this 
induction of AhR expression and activation could be due to responses by type I IFNs, IFNα and 
IFNβ, or JAK-STAT signaling, all of which are viral-induced stimulators of IDO. This result 
indirectly indicates that Delta-24-RGDOX activates IDO, since Kyn, a product of IDO enzyme 
activity, is an activator of AhR.  
Additionally, Delta-24-RGDOX increased the expression of AhR in the cytoplasm and 
nucleus in HeLa cells, indicating the translocation of AhR into the nucleus by Delta-24-RGDOX. 
The translocation of AhR into the nucleus indicates activation, as this relocation leads to 
transcription of AhR target genes, which are involved in both tumorigenesis and generation of 
immunosuppression of surrounding immune cells (29).  
Complementarily, IFNγ and Delta-24-RGDOX also induced expression of IDO in murine 
cancer cell lines. These data were accompanied with the increased expression and activation (via 
increased Kyn/Trp ratios) of IDO in Delta-24-RGD and Delta-24-RGDOX treated mouse brain 
tumors.  
Overall, these results suggested that increased expression and activation of proteins from 
the IDO-Kyn-AhR cascade results from oncolytic adenoviral infection, which could hinder anti-
tumor viral responses via immunosuppression.  These results suggest that IDO is a proper 
therapeutic target and that IDO inhibitors can be combined with oncolytic adenoviruses, such as 
Delta-24-RGDOX to enhance the anti-glioma effect of virotherapy. 
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Chapter 5: Inhibition of IDO does not hinder Delta-24-RGDOX infection, replication, or viral-
induced cytopathic ability in human and murine glioma cells. 
 
Rationale and Expectations 
Several studies demonstrated the role of the IDO pathway in attenuating the replication of 
pathogens such as cytomegalovirus, measles, herpes simplex virus, and vaccinia virus (166-169). 
It is important to mention that the effect of IDO was due, at least in part, to the depletion of Trp, 
because adding supra-physiological levels of exogenous Trp restored viral replication (170).  
The depletion of Trp by an activated IDO is directly correlated to the production of the 
metabolite Kyn, which is an activating ligand of AhR. Emerging data have shed light on an 
unexpected role of the ligand-activated transcription factor AhR in transducing the function of 
IDO in cancer cells (30). Of interest, the AhR pathway modulates the expression of the cell cycle 
regulators p27 and p21 at the transcriptional level (171). These cyclin-dependent kinase inhibitors 
negatively regulate progression of the cell cycle by inducing G1 and G2 arrest and, thus, 
restricting the virus access to the S-phase machinery required for viral DNA replication (80, 172). 
In fact, in experiments performed by other laboratories, deletion of p27 or p21 were shown to 
facilitate the replication and oncolytic effect of Delta-24 (173).  
Based on these observations, we hypothesized that activation of the IDO molecular 
pathway will attenuate the anti-glioma effect of Delta-24-RGDOX by both depleting the infected 
cells of the essential amino acid tryptophan and inducing AhR-mediated upregulation of the 
potent inhibitors of cell cycle progression, p21 and p27.  
Since we have shown the expression and activation of both IDO and AhR in response to 
Delta-24-RGDOX in vitro in human and murine glioma cell lines, we expected that there would 
be enhancement of viral activity in the presence of an IDO inhibitor. Thus, to test our hypothesis, 
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we employed the cell lines, GL261-5, GSC 8-11, GSC 13, GSC 20, and GSC-005, and infected 
them with Delta-24-RGDOX with or without IDO inhibitor treatment using either BGB-7204 
(direct IDO enzyme inhibitor) or Indoximod (Trp mimetic) and measured viral replication via a 
hexon titration, expression of viral proteins fiber and E1A, and viral-induced cytopathic ability 
via a commercially available cell viability kit. Based on data from previous publications and 
results from our studies from Chapter 4 we expected the following: 
1) In the GL261-5 cell line, we did not expect Delta-24-RGDOX to replicate, since 
we have shown in the past that this cell line is does not permit replication of the 
adenovirus (91). As such, we did not expect any changes in viral activity of Delta-
24-RGDOX in GL261-5 that were also treated with an IDO inhibitor. This cell line 
served as our negative control.  
2) Viral activity, including replication, expression of fiber, and viral-induced 
cytopathic ability of Delta-24-RGDOX will occur in replication-permissive cell 
lines, GSC-8 GSC 8-11, GSC 13, GSC 20, and GSC-005. This viral activity will 







To ascertain the effect of IDO activity on virus activity, we studied viral infection, viral 
replication, and viral-induced cytopathic ability of Delta-24-RGDOX in GL261-5, GSC 8-11, 
GSC 13, GSC 20, and GSC-005 with or without IDO inhibition using either BGB-7204 or 
Indoximod. BGB-7204 is a direct IDO enzyme inhibitor (provided by Dr. Derek Wainwright, 
Northwestern University, Feinberg School of Medicine). Indoximod is a Trp-mimetic that can 
provides an artificial supplement of Trp.  
As we expected, mouse glioma cell line, GL261-5, our negative control, did undergo 
infection by Delta-24-RGDOX, as indicated by clear expression of viral infection protein, E1A, 
but was not capable of viral replication (Figure 11A and 11B, respectively). Still, after infection 
with a high multiplicity of infection (MOI), the GL261-5 cells endured substantial viral-induced 
cell death over time (Figure 11C). When we infected GL261-5 with Delta-24-RGDOX in the 
presence of an IDO inhibitor (either BGB-7204 or Indoximod), the infection, viral replication, 
and viral-induced cytopathic ability remained unchanged compared to Delta-24-RGDOX 
infection alone (Figure 11).  
Contrary to our expectations, Figure 12A shows that Delta-24-RGDOX replication via 
hexon titration levels were unchanged when BGB-7204 was added to the cultures of human GSC 
8-11, GSC 13, and GSC 20 glioma cells. Similarly, as seen in Figure 12B, the expression of viral 
replication protein, fiber, was unchanged and viral infection protein, E1A, was still present when 
we added BGB-7204 to Delta-24-RGDOX infected cultures. Correspondingly, the viral-induced 
cytopathic ability was unchanged when we added BGB-7204 to Delta-24-RGDOX infected 
cultures, as seen in Figure 12C.  
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Notably, the GSC-005 cell line showed enhancement of viral replication by hexon 
titration, fiber expression, and viral-induced cytopathic ability of Delta-24-RGDOX in the 
presence of BGB-7204, as seen in Figures 13A-C.  
These results suggest that viral function of Delta-24-RGDOX remains unchanged and can 





Figure 11: Inhibiting IDO does not alter Delta-24-RGDOX infection, replication, or 
viral-induced cytopathic ability in murine GL261-5 glioma cells.  
GL261-5 cells were tested for Delta-24-RGDOX infection, replication, and viral-induced 
cytopathic ability with or without IDO inhibition. Cells were untreated (Mock), infected with 
UV-inactivated Delta-24-RGDOX, infected with Delta-24-RGDOX at 150 MOI, or treated 
with combined Delta-24-RGDOX and IDO inhibitor, BGB-7204 or Indoximod, at indicated 
concentrations.  Panel (A) shows viral replication of Delta-24-RGDOX or combined Delta-
24-RGDOX and BGB-7204 or Indoximod. The column graph shows the log concentration of 
the virus (pfu/mL). The cyan bar represents the initial concentration of Delta-24-RGDOX, 
and the subsequent bars show the concentration of Delta-24-RGDOX or combined Delta-24-
RGDOX and BGB-7204 or Indoximod after infection of the cells for 48 hours, which was 
measured using a hexon titration assay in 293 cells. Panel (B) shows expression of viral 
infection protein, E1A, under different treatments. The cells were treated with the indicated 
treatment for 48 hours, and proteins were extracted and blotted for E1A and tubulin. Panel 
(C) shows viral-induced cytopathic ability of Delta-24-RGDOX or combined Delta-24-
RGDOX and BGB-7204 or Indoximod. The cells were seeded in a 96 well plate and 
appropriately treated up to 120 hours, and viral-induced cytopathic effects was measured 
every 24 hours using the commercially available ViralToxGlo Assay (Promega), which 
quantifies cell viability via ATP levels. The graph shows the percent viability normalized to 
the mock infected cells.  
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Figure 12:  Inhibiting IDO does not alter Delta-24-RGDOX infection, replication, and 
viral-induced cytopathic ability in human glioma stem cells.  
Patient-derived human glioma cells, GSC-11, GSC-13, and GSC-20 were tested for Delta-
24-RGDOX infection, replication, and viral-induced cytopathic ability with or without IDO 
inhibition. Cells were untreated (Mock), infected with UV-inactivated Delta-24-RGDOX, 
infected with Delta-24-RGDOX at 25 MOI, or treated with combined Delta-24-RGDOX and 
IDO inhibitor, BGB-7204, at 150nM.  Panel (A) shows viral replication of Delta-24-RGDOX 
or combined Delta-24-RGDOX and BGB-7204 of the indicated cell line. The column graph 
shows the log concentration of the virus (pfu/mL). The cyan bar represents the initial 
concentration of Delta-24-RGDOX, and the subsequent bars show the concentration of 
Delta-24-RGDOX or combined Delta-24-RGDOX and BGB-7204 after infection in the 
indicated cell line for 48 hours, which was measured using a hexon titration assay in 293 
cells. Panels (B) shows expression of viral replication protein, fiber, and viral infection 
protein, E1A, in Delta-24-RGDOX or combined Delta-24-RGDOX and BGB-7204 treated 
cells. The cells were treated with the indicated treatment for 48 hours, and proteins were 
extracted and blotted for fiber, E1A, and tubulin. Panel (C) shows viral-induced cytopathic 
ability of Delta-24-RGDOX or combined Delta-24-RGDOX and BGB-7204 in indicated 
cells. The indicated cell lines were seeded in a 96 well plate and appropriately treated up to 
168 hours, and viral-induced cytopathic effects was measured every 24 hours using the 
commercially available ViralToxGlo Assay (Promega), which quantifies cell viability via 
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Figure 13:  Inhibiting IDO enhances Delta-24-RGDOX replication and viral-induced 
cytopathic ability in murine glioma stem cell line, GSC-005.  
Murine glioma cell line, GSC-005, was tested for Delta-24-RGDOX infection, replication, 
and viral-induced cytopathic ability with or without IDO inhibition. Cells were untreated 
(Mock), infected with UV-inactivated Delta-24-RGDOX, infected with Delta-24-RGDOX at 
100 MOI, or treated with combined Delta-24-RGDOX and IDO inhibitor, BGB-7204, at 
50nM.  Panel (A) shows viral replication of Delta-24-RGDOX or combined Delta-24-
RGDOX and BGB-7204. The column graph shows the log concentration of the virus 
(pfu/mL). The cyan bar represents the initial concentration of Delta-24-RGDOX, and the 
subsequent bars show the concentration of Delta-24-RGDOX or combined Delta-24-RGDOX 
and BGB-7204 after infection for 48 hours, which was measured using a hexon titration assay 
in 293 cells. Panel (B) shows expression of viral replication protein, fiber, and viral infection 
protein, E1A, in Delta-24-RGDOX or combined Delta-24-RGDOX and BGB-7204 treated 
cells. The cells were treated with the indicated treatment for 48 hours, and proteins were 
extracted and blotted for fiber, E1A, and tubulin. The ratio of fiber/tubulin were acquired by 
finding the ratio of pixels of fiber and tubulin using Image J software. Panel (C) shows viral-
induced cytopathic ability of Delta-24-RGDOX or combined Delta-24-RGDOX and BGB-
7204 of the cells. The cells were seeded in a 96 well plate and appropriately treated up to 96 
hours, and viral-induced cytopathic effects was measured every 24 hours using the 
commercially available ViralToxGlo Assay (Promega), which quantifies cell viability via 
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 In Chapter 4, we established the induction of IDO or AhR expression or activation in 
response to Delta-24-RGDOX infection in vitro. As such, we initially believed that blockade of 
IDO in vitro in Delta-24-RGDOX infected human and murine glioma cells would enhance viral 
activity, on the basis that IDO blockade would decrease Trp depletion and reverse potential AhR 
inhibitory effects of cell cycle progression (171).   
Interestingly, in the GSC-005 cell line, viral replication and viral-induced cell death 
induced by Delta-24-RGDOX increased in the presence of an IDO inhibitor. However, when we 
infected GSC8-11, GSC13, and GSC20 with Delta-24-RGDOX in the presence of an IDO 
inhibitor, we observed no changes in viral replication or viral-induced cytopathic ability compared 
to Delta-24-RGDOX infection alone. The results from the human glioma stem cells mirrored the 
result of our negative control, GL261-5. Still, it is noteworthy to mention that even with treatment 
with these IDO inhibitors, the viral activity is maintained, strengthening our rationale that IDO 
inhibitors are a good candidate to be combined with Delta-24-RGDOX.  
This result is important because it shows that there are no unwanted drug interactions 
between the virus and the IDO inhibitors. Furthermore, these contrasting results between GSC-
005 and the other cell lines underscore the complexity of viral activity in the context of the IDO-
Kyn-AhR pathway.  
In conclusion, treatment of murine and human glioma cells with an IDO inhibitor has no 
effect or a positive effect on adenovirus replication suggesting that adding IDO inhibitors with 




Chapter 6: Survival advantage in IDO-KO mice treated with Delta-24-RGDOX compared to 
WT mice.  
 
Rationale and Expectations 
In the previous chapters, we demonstrated that Delta-24-RGDOX infection of cancer cells 
induces expression and activation of IDO and AhR. This suggests that despite the anti-tumor 
responses we can generate using Delta-24-RGDOX, immunosuppression can still be maintained 
by an active IDO and AhR. We additionally showed that inhibiting IDO in cancer cell cultures 
infected with Delta-24-RGDOX does not alter viral replication or viral-induced cytopathic ability.  
Our previous studies proved that glioma bearing mice treated with Delta-24-RGDOX 
survive longer than mice treated with PBS (91). To ensure that the therapeutic effect of Delta-24-
RGDOX is maintained under IDO blockade, we tested the survival in glioma bearing C57BL/6 
IDO-knock out (KO) (Jackson Laboratory) mice treated with PBS or Delta-24-RGDOX. Based 
on our in vitro data showing that viral activity of Delta-24-RGDOX is maintained when we inhibit 
IDO, we expected the following: 
1) All glioma bearing IDO-KO mice treated with PBS will die. 
2) Glioma bearing IDO-KO mice treated with Delta-24-RGDOX will have a longer 
durable survival compared to PBS-treated mice.  
In addition to determining if the therapeutic efficacy of Delta-24-RGDOX is maintained 
in IDO-KO mice, we also wanted to ascertain whether targeting IDO in combination with Delta-
24-RGDOX would provide enhanced therapeutic responses in glioma bearing mice. More 
specifically, to dissect any potential off-target effects of the IDO inhibitors that might mask the 
predominant effects on the anti-tumoral immunity induced by the proposed therapy of combined 
Delta-24-RGDOX and IDO inhibitor, we tested the anti-glioma effect of Delta-24-RGDOX using 
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IDO-KO mice. In doing so, we were also able to determine the feasibility of combining IDO 
inhibitors with Delta-24-RGDOX for the treatment of murine glioblastoma.  
IDO is also involved in numerous immunosuppressive mechanisms, such as the 
differentiation of naïve CD4+ T cells into the immunosuppressive regulatory T cell and the 
induction T effector anergy or apoptosis via Trp depletion (27). Thus, by testing the anti-glioma 
effect of Delta-24-RGDOX in IDO-KO mice and comparing them to wild-type (WT) mice using 
IDO-WT glioma models, we can generalize the IDO effects of the host immune system and its 
relationship to therapeutic responses.  Based on these immunosuppressive mechanisms employed 
by IDO, the IDO-KO mice should have decreased immunosuppressive mechanisms.  
We expected the following results: 
1) All glioma bearing mice treated with PBS will die regardless of genotype. 
2) The deficient function of IDO in IDO-KO mice will enhance the therapeutic 
efficacy of Delta-24-RGDOX against glioma, leading to longer and more durable 
survival compared to WT mice. 
3) These experiments will offer strong evidence that the effects of the IDO inhibitors 






Delta-24-RGDOX prolongs survival of IDO-KO glioma bearing mice.  
Our previous in vitro results indicated that the inhibition of IDO did not alter viral 
replication or viral induced cytopathic ability. To validate that inhibition of IDO still allows for 
an oncolytic ability in vivo, we monitored the survival of IDO-KO C57BL/6 mice (The Jackson 
Laboratory) bearing GL261-5 brain tumors after treatment with either PBS or Delta-24-RGDOX. 
As seen in Figure 14, we demonstrated the oncolytic effect of Delta-24-RGDOX under the 
extreme case of IDO inhibition via the IDO KO mice, as indicated by the significant delay in 
median days of survival (55 vs 41.5 days, p = 0.0006) and presence of more long-term survivors 
compared to PBS treated mice (30% vs 0%, p = 0.0006). 
 
Glioma bearing mice of the IDO-KO genotype survive longer than the WT genotype when treated 
with Delta-24-RGDOX.  
We then wanted to ascertain whether the survival of glioma bearing mice can be enhanced 
in IDO-KO mice compared to WT mice when treated with Delta-24-RGDOX. Thus, we used WT 
or IDO-KO C57BL/6 mice, implanted them with GSC-005 cells, and treated them intratumorally 
with either PBS or Delta-24-RGDOX. As seen in Figure 15, expectedly, all the PBS treated mice 
died, regardless of genotype (p = 0.6967). Interestingly, the IDO-KO mice had a longer median 
survival (107.5 vs 55 days, p = 0.0028) and more long-term survivors (20% vs 11.1%, p = 0.0028) 
compared to WT mice when treated with Delta-24-RGDOX. These data corroborate our in vitro 
data of Figure 13, which showed that in the GSC-005 model, viral activity, including replication 




Figure 14: Delta-24-RGDOX prolongs survival of IDO-KO glioma bearing mice. 
Panel (A) shows the treatment scheme of this survival study. IDO-KO C57BL/6 mice were 
bolted on day -7, followed by an implantation of 5x10
4
 GL261-5 cells on day 0. On day 7, 
mice were split into their respective groups, including PBS or Delta-24-RGDOX treatments. 
When applicable, mice received an intratumoral injection of Delta-24-RGDOX (2.5 x 10
7 
pfu/dose) on days 7, 9, and 11. Survival was monitored over 100 days. Panel (B) shows a 
survival plot of IDO-KO mice bearing GL261-5 tumors treated with PBS (n=10) or Delta-
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Figure 15: Glioma bearing mice of the IDO-KO genotype survive longer than the WT 
genotype when treated with Delta-24-RGDOX. 
Panel (A) shows the treatment scheme of this survival study. Mice were bolted on day -7, 
followed by an implantation of 5x10
4
 GSC-005 cells on day 0. On day 7, mice were split into 
their respective groups including PBS or Delta-24-RGDOX treatments in either WT or IDO-
KO C57BL/6 mice. When applicable, mice received an intratumoral injection of Delta-24-
RGDOX (2.5 x 10
7 
pfu/dose) on days 7, 9, and 11. Survival was monitored over 200 days. 
Panel (B) shows a survival plot of IDO-KO or WT mice bearing GSC-005 tumors treated 
with PBS (WT, n=6; IDO-KO, n=8) or Delta-24-RGDOX (WT, n=9; IDO-KO, n=10). I.C., 
intracranial. I.T., intratumoral. 
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The oncolytic and therapeutic effect of armed oncolytic adenoviruses, including Delta-24-
RGDOX, in glioma-bearing mice has been proven in our lab many times (91, 94, 174). First, to 
ensure the therapeutic effect of Delta-24-RGDOX during on-target IDO blockade, we implanted 
IDO-KO mice with murine glioma cells and treated them with PBS or Delta-24-RGDOX. Here, 
Delta-24-RGDOX treated mice survived longer than PBS treated mice in glioma bearing IDO-
KO mice, suggesting that the oncolytic ability of Delta-24-RGDOX maintains its therapeutic 
effects against murine glioma under IDO depletion. 
Next, to strengthen our rationale to combine IDO inhibitors with Detla-24-RGDOX for 
the treatment of glioma, we compared the survival of IDO-KO mice to WT mice bearing gliomas 
that were treated with either PBS or Delta-24-RGDOX. The utilization of the IDO-KO mice 
provides a precise evaluation of the on-target blockade of the IDO pathway combined with Delta-
24-RGDOX. This experiment revealed that the IDO-KO mice have a survival advantage over WT 
mice when treated with Delta-24-RGDOX. This study also suggests that the effect of IDO 
immunosuppression is generated from the host immune system, rather than the glioma cells, and 
that targeting IDO in addition to treatment with Delta-24-RGDOX would be beneficial. 
Additionally, this result of increased survival of the IDO-KO mice compared to the WT mice 
suggest that the enhanced therapeutic effect is from the on-target inhibition of IDO.  
Altogether, these data demonstrate the role of IDO as a negative regulator of the Delta-
24-RGDOX-mediated anti-glioma effect and supports the therapeutic use of IDO inhibition 






Chapter 7: Treatment of brain tumor-bearing mice with the combination of IDO inhibitors and 
Delta-24-RGDOX results in a survival advantage over single agent treatments and induces anti-
glioma immune memory.  
 
Rationale and Expectations 
Data from our clinical trials (175) and preclinical mechanistic studies (91, 94, 174) suggest 
that the Delta-24-RGD and Delta-24-RGDOX infection of cancer cells elicits an immune response 
against the virus that eventually shifts to an anti-tumor immune response, providing the rationale 
to use immunomodulators as adjuvants to enhance the anti-tumor immune component of the 
virotherapy.  
IDO gained the interest of oncologists as a targetable pathway in different malignancies, 
including malignant gliomas (23, 27, 30, 39, 40, 52, 57). Several pre-clinical studies have shown 
that IDO inhibitors enhance the therapeutic effects of chemotherapy, cancer vaccines, or 
immunotherapy (18, 48-51). For that reason, clinical trials are underway to test the triple 
combination of IDO and PD-1 inhibitors with chemotherapy (NCT03661320) or with cancer 
vaccines (NCT03519256).  
There is a strong rationale for combining oncolytic viruses and IDO inhibitors: a) IFN is 
the main response against adenoviruses such as Delta-24-RGDOX, and IDO is an IFN-
responsive gene (152); b) IDO activity is a major response of the host cell against pathogens, 
including viral infections (166-169), and c) IDO is found overexpressed in many malignancies 
including glioblastoma (23) and activated in the course of viral infections (166-169). Consistent 
with these previously published observations, we proved in the current study that IFNγ induced 
IDO expression and that Delta-24-RGDOX induced expression and activation of IDO and AhR 
in human or murine glioma cells. Gathering all this data, we expected that the combined Delta-
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24-RGDOX and IDO inhibitor treatment would enhance survival of glioma bearing mice 
compared to single agent treatments. More specifically, we expected the following: 
1)  Brain tumor-bearing mice treated with combined Delta-24-RGDOX and IDO 
inhibitor will have longer and more durable survival compared to glioma bearing mice 
treated with Delta-24-RGDOX or the IDO inhibitor alone.  
2) The histopathological staining will show that the mice treated with combined Delta-
24-RGDOX and IDO inhibitor will have the smallest tumor mass compared to either 
single agent treatment.  
3) Long term survivors that were previously treated with the combined Delta-24-
RGDOX and IDO inhibitor will generate immune memory against the glioma and have 





Delta-24-RGDOX combined with Trp-mimetic, 1MT or Indoximod, leads to smaller tumor mass, 
provides a greater survival advantage, and induces a more robust anti-tumor immunity than 
single agents in the treatment of solid tumors.  
To determine the therapeutic efficacy of Delta-24-RGDOX combined with IDO inhibitors, 
we performed a survival study using the immunocompetent GL261-5 C57BL/6 mouse model. As 
shown in Figure 16A, a metal bolt was placed into the right skull directly above the caudate 
nucleus of each mouse under anesthesia, and 7 days later, 5 × 104 GL261-5 cells were implanted 
through the metal bolt. Starting on day 7 after tumor implantation, mice were split into 4 treatment 
groups: 1) intracranial (I.C.) PBS and PBS by oral gavage, 2) I.C. PBS and 1MT or indoximod 
by oral gavage, 3) I.C. Delta-24-RGDOX and PBS by oral gavage, and 4) I.C. Delta-24-RGDOX 
and 1MT or indoximod by oral gavage. Mice treated with Delta-24-RGDOX were infected on 
days 7, 9, and 11 at a dose of 5 × 107 pfu/mouse. Mice treated with 1MT or indoximod were 
treated twice daily, 5 days/week, for 28 days, starting 7 days after tumor implant.  As shown in 
Figure 16B, the control mice and mice treated with 1MT alone had similar survival patterns, with 
median survival times of 38.5 and 37.5 days, respectively (p > 0.9999). As expected, the mice 
treated with Delta-24-RGDOX alone had significantly prolonged survival, with a median survival 
time of 46.5 days and 20% of the mice surviving for at least 120 days (vs. control, p=0.02; vs. 
Delta-24-RGDOX plus 1MT, p=0.01). Interestingly, mice treated with the combination of Delta-
24-RGDOX and 1MT had the longest survival, with a median survival time of 108.5 days and 
50% of the mice surviving for at least 120 days (vs. control, p<0.0001; vs. Delta-RGDOX alone, 
p=0.01). Furthermore, in mice treated with the combination of Delta-24-RGDOX and Indoximod, 
hematoxylin-eosin staining revealed an observable and substantial tumor regression on day 15 
and complete eradication by day 24 (Figure 17A), which was associated with the lowest surface 
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areas of high-grade cellularity (Delta-24-RGDOX vs Delta-24-RGDOX and Indoximod, 2.10 x 
106 vs. 0.44 x 106, p= 0.0298) (Figure 17B). H&E images of individual mice are seen in Figure 
18. To confirm that the anti-tumor effect was immune mediated, the long-term survivors in the 
group treated with Delta-24-RGDOX plus 1MT were re-challenged with the same glioblastoma 
cell line and observed for survival. Importantly, all the mice previously treated with Delta-24-
RGDOX plus 1MT survived for at least 100 days, while all the untreated mice died by day 51 
(p=0.0018) (Figure 16C). These data demonstrated the generation of memory against the tumor 
by the combination of Delta-24-RGDOX and 1MT.  
We also observed an enhanced survival effect using the B16-F10 intracranial melanoma 
model, in which 14% of mice treated with Delta-24-RGDOX and Indoximod survived for at least 
26 days, compared to zero survivors in the Delta-24-RGDOX only treated group (p = 0.0140, 
Figure 19).  
 These results indicated that the combination of Delta-24-RGDOX and Trp-mimetics was 
therapeutically superior to either treatment alone in mouse models of aggressive intracranial brain 
tumors.  
 
Delta-24-RGDOX combined with the direct IDO enzyme inhibitor, BGB-7204, leads to lower 
tumor mass and provides a greater survival advantage compared to single agents in murine 
glioblastoma.  
Because 1MT and Indoximod are Trp-mimetics, they are not considered direct IDO 
enzyme inhibitors. Thus, we also tested the therapeutic effect of Delta-24-RGDOX in the context 
of direct IDO enzyme inhibition using BGB-7204 (provided by Dr. Derek Wainwright). BGB-
7204 is a novel pre-clinical direct IDO enzyme inhibitor that has shown therapeutic efficacy when 
combined with radiation and anti-PD-1 monoclonal antibodies in murine models of glioma (57). 
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We tested the antitumor effects in GSC-005 glioma bearing mice and submitted them to four 
different treatment groups included treatment groups: 1) I.C. PBS and vehicle by oral gavage 
(control), 2) I.C. PBS and BGB-7204 by oral gavage 3) I.C. Delta-24-RGDOX and vehicle by 
oral gavage, and 3) I.C. Delta-24-RGDOX and BGB-7204 by oral gavage. Mice treated with 
Delta-24-RGDOX were infected on days 9 and 11 at a dose of 2.5 × 107 pfu/mouse. Mice treated 
with BGB-7204 were treated twice daily, 5 days/week, for 28 days starting on day 7. In mice 
treated with the combination of Delta-24-RGDOX and BGB-7204, hematoxylin-eosin staining 
revealed complete eradication by day 24 (Figure 20A), which associated with the lowest surface 
areas of high-grade cellularity compared to all other treatment groups (Delta-24-RGDOX vs 
Delta-24-RGDOX and BGB-7204, 7.64 x 105 vs. 0.42 x 105, p = 0.0261) (Figure 20B). H&E 
images of individual mice are seen in Figure 21. These results indicated that the combination of 
Delta-24-RGDOX and an IDO inhibitor was reproducible in a third murine glioma model, and 







Figure 16: Combined Delta-24-RGDOX and 1MT provides a survival advantage over 
either treatment alone and induces anti-glioma memory in a murine immunocompetent 
glioma model.  
(A) Mice were bolted on day -7, followed by injection of 5x104 GL261-5 cells on day 0. On 
day 7, mice were split up into four treatment groups including PBS (control), 1MT, Delta-24-
RGDOX, or combined 1MT and Delta-24-RGDOX. Mice received Delta-24-RGDOX (5x107 
pfu/mouse) on days 7, 9, and 11. 1MT treatment started on day 7 and lasted until day 35. 
Panel (B) shows a survival plot of C57BL/6 mice bearing GL261-5 tumors treated with PBS, 
1MT, Delta-24-RGDOX, or combined 1MT and Delta-24-RGDOX (n=10). Mice surviving 
120 days from the combined Delta-24-RGDOX and 1MT treatment group were re-challenged 
with the same cell line on the contralateral hemisphere and observed for survival. Panel (C) 
shows a survival plot of combined 1MT and Delta-24-RGDOX treated mice re-challenged 
with the same cell line on the contralateral brain hemisphere compared to control naïve mice 
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log-rank test, p > 0.05 is ns






























Figure 17: Combined Delta-24-RGDOX and Indoximod leads to tumor regression in a 
murine immunocompetent glioma model.  
Following the same treatment schedule as in Figure 16, mice were sacrificed 15 and 24 days 
after tumor implantation, brains were collected in formalin for embedding, sectioning, and 
H&E staining. Panel (A) shows representative H&E staining images of GL261-5 bearing 
mouse brains treated with PBS, Indoximod, Delta-24-RGDOX, or combined Indoximod and 
Delta-24-RGDOX 15- and 24-days post tumor implantation. Panel (B) shows the average 
tumor areas in differently treated mice on day 15 of GL261-5 bearing C57BL/6 mouse brains. 
Aperio ImageScope software was used to acquire images and to measure areas of high-grade 

















All scale bars set to 2 mm. 
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Figure 18: Combined Delta-24-RGDOX and Indoximod treatment induces tumor 
regression in GL261-5 bearing mice.  
Following the same treatment schedule as in Figure 16, mice were sacrificed on (A) day 15 
or (B) day 24, and brains were collected in 10% buffered formalin and transferred to 70% 
ethanol after 24 hours. Brain tumor coronal sections were embedded in paraffin and sectioned 
in 5µm slices using a microtome and affixed onto positively charged glass slides. Slides were 
subjected to hematoxylin and eosin staining via conventional methods. Slides were scanned 







Figure 19: Combined Delta-24-RGDOX and Indoximod treatment shows a survival 
advantage in B16-melanoma brain tumor bearing mice.  
Panel (A) shows the treatment schedule, where mice were bolted on day -7, followed by 
injection of 1x103 B16 cells on day 0. On day 7, mice were split up into three treatment groups 
including PBS (control, n=6), Delta-24-RGDOX (n=7), or combined Delta-24-RGDOX and 
Indoximod (n=7). Mice received Delta-24-RGDOX (5x107 pfu/mouse) on days 7, 9, and 11 
(when applicable). Indoximod treatment started on day 7 and lasted an additional 28 days 
(when applicable). Panel (B) shows a survival plot of the differently treated C57BL/6 mice 
bearing B16 brain tumors. I.C., intracranial, I.T., intratumoral. OG, oral gavage. BID, bis in 
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Figure 20: Combined Delta-24-RGDOX and BGB-7204 treatment results in the smallest 
tumor mass compared to single agent treatments in GSC-005 brain tumor bearing mice.  
Mice were bolted on day -7, implanted with the 5x10
4
 GSC-005 cells on day 0, injected with 
Delta-24-RGDOX (2.5x10
7
 pfu/mouse in 5µL) or PBS on days 9, and 11, and treated with 
100 mg/kg BID per mouse of BGB-7204 on days 7-24. Panel (A) shows representative H&E 
staining images of coronal mouse sections on day 24. Panel (B) shows average tumor areas in 
differently treated mice on day 24 of these GSC-005 bearing C57BL/6 mouse brains. The 
methods described in Figure 17 were used.  Column graph values represent mean ± SD 
(n=3+). 
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Figure 21: Combined BGB-7204 and Delta-24-RGDOX treatment induces tumor 
regression in GSC-005 tumor bearing mice. 
The figure shows H&E images of mouse brain coronal sections of C57BL/6 GSC-005 bearing 
mice. Mice were bolted on day -7, implanted with the 5x10
4
 GSC-005 cells on day 0, injected 
with Delta-24-RGDOX (2.5x10
7
 pfu/mouse in 5µL) or PBS on days 9, and 11, and treated 
with 100 mg/kg BID per mouse of BGB-7204 on days 7-24. Mice were sacrificed on day 24, 
and brains were collected in 10% buffered formalin and transferred to 70% ethanol after 24 
hours. Brain tumor coronal sections were embedded in paraffin and sectioned in 5µm slices 
using a microtome and affixed onto positively charged glass slides. Slides were subjected to 
hematoxylin and eosin staining via conventional methods. Slides were scanned using the 
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In the current study, we have provided data to support our rationale to combine IDO 
inhibitors and Delta-24-RGDOX for the treatment of murine glioma including: 1) Delta-24-
RGDOX increases IDO expression and activation and 2) the on-target blockade of IDO enhances 
the therapeutic efficacy of Delta-24-RGDOX. These data along with previous publications 
describing the immunosuppressive mechanisms caused by IDO (24, 27) supported our studies in 
determining the efficacy of the combination of IDO inhibitors with Delta-24-RGDOX for the 
treatment of murine glioma. 
To assess the combination of Delta-24-RGDOX combined with IDO inhibitors, we used 
several murine tumor models that were syngeneic to the immunocompetent C57BL/6 mouse, 
including murine gliomas, GL261-5 and GSC-005, and murine melanoma, B16. The survival and 
histopathology of the tumor-bearing brains of these mice were studied following treatments with 
PBS, IDO inhibitor alone, Delta-24-RGDOX alone, or the combination of Delta-24-RGDOX and 
IDO inhibitor.  The IDO inhibitors used included Trp-mimetics, 1MT and Indoximod, and direct 
IDO enzyme inhibitor, BGB-7204. These studies resulted in the following conclusions: 
1) Mice bearing intracranial tumors including the immunocompetent GL261-5, GSC-005, 
and the B16 (melanoma) models benefit from Delta-24-RGDOX treatment; when IDO 
inhibitors are combined with Delta-24-RGDOX, the therapeutic effect increases.  
2) The enhanced therapeutic effect of the combination treatment was evident with both Trp-
mimetics (1MT or Indoximod) and direct IDO enzyme inhibitors (BGB-7204).  
3) The enhanced therapeutic effect was indicated by more survival and greater decreases in 
the tumor mass in brain tumor bearing mice treated with combined Delta-24-RGDOX and 
IDO inhibitor treatment compared to mice treated with Delta-24-RGDOX alone or IDO 
inhibitor alone.  
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4) The minimal therapeutic effect of treatment by the IDO inhibitor alone indicated that IDO 
inhibitors may be effective when combined with another agent.  
5) The rejection of a second tumor implantation in mice previously treated with the 
combination of Delta-24-RGDOX and IDO inhibitors suggests induction of an anti-
glioma immune memory response.  
6) There were no obvious signs of general toxicity by the mice, including hunched posture, 
diarrhea, or weight loss, by the combination treatment.  




Chapter 8: The therapeutic efficacy of the combination of IDO inhibitor and Delta-24-RGDOX 
treatment requires CD4+ helper T Cells. 
 
Rationale and Expectations 
Thus far, we can postulate that Delta-24-RGDOX induces both tumor-promoting and anti-
tumor immune responses, as evident by 1) the RNA-sequencing data, 2) the induction of IDO 
expression and activation by Delta-24-RGDOX in glioma bearing mice, 3) the greater survival 
effect in Delta-24-RGDOX treated mice compared to PBS treated mice bearing gliomas, and 4) 
the enhanced therapeutic responses in glioma bearing mice by the combined Delta-24-RGDOX 
and IDO inhibitor treatment compared to treatment with Delta-24-RGDOX alone. We can further 
speculate that the enhanced therapeutic efficacy of the combination compared to single agent 
treatments is due to the generation of an immune memory against glioma antigens as indicated by 
our previous survival study that showed 100% survival in re-challenged mice that were previously 
treated with the combination therapy.  
To further evaluate to which extent the immune component, particularly the role of T-
helper cells, is responsible for the anti-cancer effect, we depleted CD4+ T cells in 
immunocompetent GL261-5 glioma bearing mice treated with Delta-24-RGDOX or the 
combination Delta-24-RGDOX and IDO inhibitor. The depletion of specific CD4+ T cells can be 
achieved by serial intraperitoneal injections of CD4 neutralizing antibodies (BioXCell-
InVivoMAb anti-mouse CD4, clone GK1.5) in mice.  
OX40 is a costimulatory receptor that is primarily activated on CD4+ T cells and is heavily 
involved in regulation of CD4+ and CD8+ T cell proliferation, differentiation, and survival (92, 
93, 176, 177). These OX40 activation mechanisms are supported by our previous studies that 
demonstrated a significant survival effect of Delta-24-RGDOX using the immunocompetent 
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GL261-5 glioma model; by contrast, when GL261-5 glioma cells were implanted in athymic 
immunodeficient mice and treated with Delta-24-RGDOX, 100% of the mice died, indicating the 
dependence of Delta-24-RGDOX on the immune system for therapeutic efficacy (91).  
Patterns of survival in mice receiving treatment of Delta-24-RGDOX alone or together 
with the administration of an IDO inhibitors plus the CD4 neutralizing antibody should provide 
mechanistic data about the role of CD4+ T cells on oncolytic virotherapy.  
Based on the current literature and our previous findings, we expected the following:  
1) Glioma bearing mice treated with Delta-24-RGDOX and the CD4 neutralizing 
antibody will have a similar survival pattern to the control treated mice.  
2) Glioma bearing mice treated with the combination of Delta-24-RGDOX, the IDO 
inhibitor, and the CD4 neutralizing antibody will have a similar survival pattern to the 
control treated mice.  
3) Glioma bearing mice treated with the combination of Delta-24-RGDOX, the IDO 
inhibitor, and a control antibody will survive longer than the groups treated with the 
CD4 neutralizing antibody. 
4) CD4+ T cell immune responses against the virus and tumor is required for an antitumor 
effect in glioma bearing mice treated with Delta-24-RGDOX or combined Delta-24-




To understand the effects of the helper T cell population on the efficacy of combined 
Delta-24-RGDOX and IDO inhibitor treatment in murine glioblastoma, we performed a survival 
experiment using the GL261-5 C57BL/6 mouse model. The methodology is described in Figure 
22A, where mice were bolted 7 days prior to an intracranial 5 x 104 GL261-5 cell injection 
followed by three doses of Delta-24-RGDOX (5 x 107 pfu/mouse) on days 7, 9, and 11. Treatment 
groups included 1) control (PBS) + IgG, 2) Delta-24-RGDOX + anti-CD4 (for depletion of helper 
T cells), 3) Delta-24-RGDOX + Indoximod + anti-CD4, and 4) Delta-24-RGDOX + Indoximod 
+ IgG. Figure 23 shows validation of CD4+ T cell depletion.  
As expected, the control group had a median survival of 40 days (Figure 22B). 
Interestingly, the mice treated with the CD4 depletion antibody and Delta-24-RGDOX or 
combined Delta-24-RGDOX and Indoximod had a median survival of 33 or 36 days, respectively, 
which mirrored the control group treated with PBS + IgG (PBS + IgG vs Delta-24-RGDOX + 
anti-CD4, p = 0.0732; vs. Delta-24-RGDOX + Indoximod + anti-CD4, p = 0.5989). This indicates 
the dependency of Delta-24-RGDOX and/or Indoximod on the T helper CD4+ population for the 
therapeutic and long-term survival effect. Mice treated Delta-24-RGDOX + Indoximod + IgG had 
a 100% survival after 100 days, confirming the therapeutic efficacy of combined Delta-24-
RGDOX with a Trp-mimetic (Indoximod) in this brain tumor model (Delta-24-RGDOX + 
Indoximod + anti-CD4 vs. Delta-24-RGDOX + Indoximod + IgG, p < 0.0001). 









Figure 22: Therapeutic efficacy of combined IDO inhibition and Delta-24-RGDOX 
treatment requires CD4+ helper T cells.  
Panel (A) shows the treatment schedule, where mice were bolted on day -7, followed by 
intracranial injections of 5x104 GL261-5 cells on day 0. On day 7, mice were split up into four 
treatment groups including 1) PBS (control) plus IgG control antibody (BioXCell-
InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin), 2) Delta-24-
RGDOX plus CD4 neutralizing antibody (BioXCell-InVivoMAb anti-mouse CD4 (clone 
GK1.5)), 3) Delta-24-RGDOX and Indoximod plus CD4 neutralizing antibody, and 4) Delta-
24-RGDOX and Indoximod plus IgG control antibody. Mice received Delta-24-RGDOX 
(5x107 pfu/mouse) on days 7, 9, and 11. Indoximod treatment started on day 7 and lasted an 
additional 28 days. Neutralizing or control antibodies were administered, intraperitoneally, 
every fourth day for nine rounds. Panel (B) shows the survival of differently treated mice.  
I.C., intracranial. I.T., intratumoral. OG, oral gavage. BID, bis in die, twice daily. 
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B 
Survival Experiment Testing CD4 depletion in Delta-24-RGDOX and/or Indoximod 
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Figure 23: CD4 neutralizing antibodies deplete CD4 populations in vivo.  
This figure supplements the survival study of GL261-5 bearing mice treated with Delta-24-
RGDOX and/or Indoximod with or without CD4 depletion antibodies, seen in Figure 22. Mice 
were treated with CD4 neutralizing antibodies (αCD4: BioXCell-InVivoMAb anti-mouse 
CD4 (clone GK1.5)) or an unreactive IgG (IgG2b: BioXCell-InVivoMAb rat IgG2b isotype 
control, anti-keyhole limpet hemocyanin) to serve as a control. On day 38 post-tumor implant, 
one mouse from each treatment was sacrificed. Spleens were collected and processed into 
single cells and stained for CD3, CD4, and CD8, then analyzed using flow cytometry.  Flow 
cytometry plots show CD4 and CD8 populations of the (A) naïve, (B) IgG2b, or (C) anti-CD4 
treated mice. D) The column graph shows the frequency of the CD4 population in the indicated 




























































Our previous studies underscore the importance of the host immune system to elicit the 
antitumor effects of Delta-24-RGDOX in glioma bearing mice (91). To further study the role of 
CD4+ T helper cells during Delta-24-RGDOX or combined Delta-24-RGDOX and IDO inhibitor 
treatment, we conducted a survival study of glioma bearing mice with these respective treatments 
with or without depletion of the CD4+ T helper cell population. 
Our results indicate that we successfully depleted the CD4+ T cell population allowing us 
to accurately determine the role of CD4+ T helper cells on the therapeutic efficacy of Delta-24-
RGDOX or combined Delta-24-RGDOX and Indoximod treatment in an immunocompetent 
murine glioma model. As such, we can make the following conclusions: 
1) The therapeutic efficacy and antitumor effect of Delta-24-RGDOX or combined Delta-
24-RGDOX and IDO inhibitor treatment requires CD4+ T cell activity of the host.  
2) The superior survival effects of combined Delta-24-RGDOX with Trp-mimetic, 
Indoximod in the GL261-5 glioma model is reproducible.  
The 100% death of glioma bearing mice caused by the depletion of the CD4+ T helper 
population is congruent with the outcomes of the enhanced OX40 receptor pathway activation 
elicited by Delta-24-RGDOX. More specifically, the OX40 receptor is a T cell activator with 




Chapter 9: The combination of Delta-24-RGDOX and IDO inhibitors increases the amount of 
intratumoral T cells and decreases the count of immune tolerant populations. 
 
Rationale and Expectations 
The IDO pathway metabolite, Kyn, activates AhR in several populations of immune-
related cells, shaping the pro-tumorigenic functions of the tumor microenvironment (27, 42, 164, 
165). Depletion of Trp, and the subsequent excess of Kyn in the tumor microenvironment results 
in suppression of T-cell function and induction of T-cell apoptosis (35). Kyn-mediated activation 
of AhR promotes FOXP3+ regulatory T cell differentiation (32, 33). In addition, the IDO-Kyn-
AhR cascade has been linked to Th17 differentiation (178, 179) of T helper cells, whose 
suppressive function has been associated with tumor immunosuppression (180). The activation of 
the IDO pathway also elicits integrated stress responses via Trp depletion leading to IL-6 cytokine 
signaling, which is essential for MDSC formation (36, 37).  
The IDO-Kyn-AhR molecular cascade may further influence the tumor microenvironment 
in the context of virotherapy because it is involved in the host immune response against viruses. 
In agreement with this data, the IDO-Kyn-AhR pathway is an important environmental modulator 
that contributes to the prevalence and severity of viral infections (181). Therefore, we were 
interested in ascertaining the extent to which the infection of gliomas by Delta-24-RGDOX 
prompts activation of the IDO-Kyn-AhR pathway in the tumor microenvironment. In fact, we 
were able to show the increased induction of IDO expression and activation in vivo in Delta-24-
RGDOX treated brain tumors compared to PBS-treated, seen in Figures 9 and 10.  
The IDO-Kyn-AhR activation after oncolytic virus administration may further contribute 
to increased tumor immunosuppression and, in turn, facilitate the glioma’s ability to evade the T-
cell immune response elicited by virotherapy. In agreement with this, we observed an enhanced 
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therapeutic efficacy of combined Delta-24-RGDOX and IDO inhibitor treatment compared to 
Delta-24-RGDOX treatment alone in murine glioma, as discussed in Chapters 7 and 8. 
Consequently, we expected that adding an IDO inhibitor to Delta-24-RGDOX would increase 
general T cell populations (CD3+, CD4+, and CD8+ T cells) and decrease immunosuppressive 
populations, such as Tregs or MDSCs, within the tumor microenvironment. More specifically, we 
expected the following: 
1) Delta-24-RGDOX treatment will increase the immunogenicity of murine gliomas. 
Particularly, Delta-24-RGDOX will increase both anti-tumor and pro-tumorigenic 
immune populations, including CD4+ T helper cells, cytotoxic CD8+ T cells, 
regulatory T cells, and myeloid derived suppressor cells. 
2) IDO inhibitors will enhance the infiltration of CD4+ T helper cells and cytotoxic CD8+ 
T cells generated by Delta-24-RGDOX in murine glioma. 
3) IDO inhibitors will decrease the infiltration of immune tolerant populations (Tregs and 




The combination of Delta-24-RGDOX with IDO inhibitors increases the frequency of 
intratumoral T cells. 
To further understand the mechanism underlying the anti-cancer effect of the combination 
of Delta-24-RGDOX and IDO inhibitors, we examined phenotypic changes of lymphocyte 
populations within the tumor from the GL261-5 or GSC-005 bearing mice treated with 1) PBS, 
2) IDO inhibitor alone, 3) Delta-24-RGDOX alone, or 4) combined IDO inhibitor and Delta-24-
RGDOX. After treating the mice with indicated treatment for 17 days, we isolated brain-
infiltrating lymphocytes and stained them to identify tumor-infiltrating CD3+ cells, T-helper CD4+ 
cells, and cytotoxic CD8+ T lymphocytes by flow cytometry. As expected, Delta-24-RGDOX 
treatment resulted in an increase in tumor-infiltrating CD3+, T-helper CD4+ cells, and cytotoxic 
CD8+ T lymphocytes per hemisphere after 17 days of treatment (Figures 24A and 27) compared 
to PBS or IDO inhibitor treated mice in both the GL261-5 and GSC-005 model. Of interest, the 
combination of Delta-24-RGDOX and IDO inhibitor treatment led to highest absolute count per 
hemisphere in the CD3+, CD4+, and CD8+ populations compared to all other groups (Figures 24A 
and 27; p < 0.05, all populations). This pattern was also confirmed in CD3+ 
immunohistochemistry, where the highest amounts of CD3+ staining density occur in mouse 
tumors treated with combined Delta-24-RGDOX and IDO inhibitor treatment (Figure 24B). 
Representative images of the CD3+ IHC for both models of individual mice are seen in Figures 





The combination of Delta-24-RGDOX with IDO inhibitors decreases the frequency of immune 
tolerant populations. 
Furthermore, to determine the tolerant immune effects within the tumor microenvironment 
produced by the combination of Delta-24-RGDOX and Indoximod, we used flow cytometry to 
analyze the populations of regulatory T cells (CD4+, FOXP3+, CD25+) and myeloid-derived 
suppressor cells (CD45+, GR1+, CD11b+) of GL261-5 brain tumors after 17 days of treatment or 
24 days after the tumor implant. RNA sequencing analyses revealed that GL261-5 tumors treated 
with Delta-24-RGDOX harbored enrichment of Treg and MDSC gene sets (Figure 28A and 28C). 
This result was validated by the flow cytometry assays, which showed that the mice treated with 
Delta-24-RGDOX alone had more Tregs and MDSCs per hemisphere than PBS-treated or 
Indoximod-treated mice had (Figure 28B and 28D). Notably, the mice treated with the 
combination of Delta-24-RGDOX and Indoximod had fewer Tregs and MDSCs than the mice 
treated with Delta-24-RGDOX only had (p < 0.0001, both populations). These data indicate the 
decrease in immune-tolerant populations when Delta-24-RGDOX was combined with IDO 





Figure 24: The combination of Delta-24-RGDOX with IDO inhibitors increases the 
absolute count per hemisphere of intratumoral T cells in murine glioma.  
Mice were bolted on day -7, then implanted with 5 x 104 GSC-005 or GL261-5 cells on day 
0; on days 9 and 11 (GSC-005) or days 7, 9, and 11 (GL261-5), the mice were intracranially 
injected with PBS, Delta-24-RGDOX (2.5 x 107 (GSC-005) or 5 x 107 (GL261-5) pfu/dose). 
IDO inhibitors (IDOi: Indoximod, 275 mg/kg or BGB-7204, 100 mg/kg, BID) were 
administered from days 7 to 24. On day 7, mice were split up into four treatment groups 
including PBS (control), IDOi, Delta-24-RGDOX, or combined IDOi and Delta-24-RGDOX. 
We sacrificed the mice on day 24. The brain tumor bearing mouse brains were collected and 
processed into single cells and enriched for immune cells using a percoll gradient. Immune 
cells were stained for CD3, then analyzed using flow cytometry. Panel (A) shows column 
graphs of absolute count of cells/hemisphere for the CD3+ T cell population. Panel (B) shows 
representative images of brain tumor sections of the differently treated mice stained for CD3 
by immunohistochemistry. Images were acquired using the Aperio ImageScope-Pathology 


































































































Figure 25: BGB-7204 enhances CD3+ T cell infiltration of Delta-24-RGDOX infected 
GSC-005 brain tumors.  
Representative images of CD3 immunohistochemistry of individual mice in the different 
treatment groups of GSC-005 brain tumor bearing mice. Mice were bolted on day -7, 
implanted with the 5x104 GSC-005 cells on day 0, injected with Delta-24-RGDOX (2.5x107 
pfu/mouse in 5µL) or PBS on days 9 and 11, and/or treated with 100 mg/kg per mouse of 
BGB-7204 on days 7-24. Mice were sacrificed on day 24, and brains were collected and fixed 
in 10% buffered formalin and transferred to 70% ethanol after 24 hours. Brain tumor coronal 
sections were embedded in paraffin and sectioned in 5µm slices onto positively charged glass 
microscope slides using a microtome. Slides were stained for anti-CD3 using 
immunohistochemistry. Slides were scanned and images were acquired using the Aperio 























































Figure 26: Indoximod enhances CD3+ T cell infiltration of Delta-24-RGDOX infected 
GL261-5 brain tumors.  
Representative images of CD3 immunohistochemistry of individual mice in the different 
treatment groups of GL261-5 brain tumor bearing mice. Mice were bolted on day -7, 
implanted with the 5x10
4
 GL261-5 cells on day 0, injected with Delta-24-RGDOX (5x10
7
 
pfu/mouse in 5µL) or PBS on days 7, 9, and 11, and/or treated with 275 mg/kg per mouse of 
Indoximod on days 7-24. Mice were sacrificed on day 24, and brains were collected and fixed 
in 10% buffered formalin and transferred to 70% ethanol after 24 hours. Brain tumor coronal 
sections were embedded in paraffin and sectioned in 5µm slices onto positively charged glass 
microscope slides using a microtome. Slides were stained for anti-CD3 using 
immunohistochemistry. Slides were scanned and images were acquired using the Aperio 
ImageScope-Pathology Slide Viewing Software.  






















































Figure 27: IDO inhibitors increase the frequency of intratumoral CD4+ and CD8+ T cell 
populations generated by Delta-24-RGDOX infection in murine gliomas.  
Following the same treatment scheme as in Figure 24, the mouse brain tumors were collected 
and processed into single cells and enriched for immune cells using a percoll gradient. 
Immune cells were stained for CD45, CD3, CD4, and CD8, then analyzed using flow 
cytometry. Column graphs show absolute count of cells per hemisphere for the (A/B) CD4+ 
and (C/D) CD8+ populations within the brain tumor microenvironment of the differently 






































































































































Figure 28:  Delta-24-RGDOX induces regulatory T cells and myeloid derived suppressor 
cells within the glioma microenvironment, which can be suppressed with the addition of 
an IDO inhibitor.  
Mice were bolted on day -7, implanted with the 5x104 GL261-5 cells on day 0, injected with 
Delta-24-RGDOX (5x107 pfu/mouse in 5µL) or PBS on days 7, 9, and 11, and/or treated with 
275 mg/kg per mouse of Indoximod on days 7-24. On day 12, RNA from the brain tumors 
were submitted to gene sequencing enrichment analysis to determine enrichment of the (A) 
Treg or (C) MDSC gene sets in PBS or Delta-24-RGDOX treated brain tumors. Mice were 
sacrificed on day 24, and brains were processed into single cells and enriched for immune 
cells using a percoll gradient. Immune cells were stained for CD45, CD3, CD4, CD8, CD25, 
FOXP3, CD11b, and GR1, then analyzed by flow cytometry. Column graphs show absolute 
count of cells per hemisphere of tumor tolerant populations, B) regulatory T cells or D) 





We developed the next generation of Delta-24-RGD by adding the OX40L to the 
backbone of the virus to enhance the immune responses via co-stimulation of the OX40 receptor 
of activated T cells. Our previously published studies show that treatment of murine glioma with 
Delta-24-RGDOX increases both immune-activating and immune-suppressing properties within 
the tumor microenvironment, including more infiltration of CD8+ T cells or higher expression of 
PD-L1 on glioma cells compared to PBS or Delta-24-RGD treatment (91). In the current study, 
we also showed that Delta-24-RGDOX can contribute to immunosuppressive properties, as 
indicated by elicitation of IDO or AhR expression and activation (Chapter 4). The enhanced 
survival of glioma bearing mice treated with combined Delta-24-RGDOX and IDO inhibitor 
treatment compared to Delta-24-RGDOX alone, as discussed in Chapter 7, also suggests a level 
of immunosuppression generated by Delta-24-RGDOX that allows immune evasion of antitumor 
responses. 
To determine how the combination treatment of Delta-24-RGDOX and IDO inhibitors 
remodels the immune landscape of the glioma microenvironment, we studied the infiltration of 
different immune populations, including CD4+ T cells, CD8+ T cells, Tregs, and MDSCs, in brain 
tumors of mice treated with PBS, IDO inhibitor alone, Delta-24-RGDOX alone, or combined 
Delta-24-RGDOX and IDO inhibitor. Based on these studies, we can make the following 
conclusions: 
1)  The infiltration of CD3+, CD4+, and CD8+ T cells by Delta-24-RGDOX can be 
enhanced with IDO inhibitors in two immunocompetent murine glioma models, GSC-
005 and GL261-5. Furthermore, we were able to show this phenomenon using both 
Trp-mimetics (Indoximod) and direct IDO enzyme inhibitors (BGB-7204).   
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2) The use of IDO inhibitors alone provides minimal immunological responses, which 
corresponds to its similar survival pattern of PBS-treated mice.  
3) In all cell populations studied, including that of CD3+ T cells, CD4+ T cells, CD8+ T 
cells, Treg, or MDSCs, there was minimal and similar absolute count/hemisphere in 
the PBS- and IDO inhibitor-treated mice.  
4) Delta-24-RGDOX treatment increased the absolute count per hemisphere of CD3+ T 
cells, CD4+ T cells, CD8+ T cells, Treg, or MDSCs, indicating the transformation of 
these non-immunogenic murine brain tumors into more immunogenic tumors. 
5) The combined Delta-24-RGDOX and IDO inhibitor treatment decreased the absolute 
count/hemisphere of the immunosuppressive Treg and MDSC populations in 
comparison to Delt-24-RGDOX single treatment.  
Overall, our studies indicates that Delta-24-RGDOX enhances infiltration of both 
immune-activating and immune-suppressive populations; in comparison, the addition of IDO 
inhibition to Delta-24-RGDOX increases the immune activating populations and decreases the 
immune suppressive populations.  This reshaping of the tumor microenvironment should favor 
the identification and destruction of the infected tumor by the immune system of the host.   
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Chapter 10: The combination of IDO inhibitors and Delta-24-RGDOX increases T-cell 
activation against tumor and viral antigen, which is negatively regulated by kynurenine. 
 
Rationale and Expectations 
Our pre-clinical studies have shown that in comparison to Delta-24-RGD, Delta-24-
RGDOX enhances the survival of glioma mice, which was accompanied by an increase in 
functional T cell responses by both brain infiltrating lymphocytes and splenocytes (91). Still, as 
discussed in this dissertation, Delta-24-RGDOX can also produce immunosuppression, as 
supported by 1) the elicitation of IDO activation in both the GL261-5 and GSC-005 murine glioma 
models and 2) the increased infiltration of immunosuppressive immune populations, Tregs and 
MDSCs.  
The activation of the IDO-Kyn-AhR pathway (Figure 29A) results in apoptosis and 
anergy of T effector cells and activation of Tregs (27, 29). The amalgamation of these 
observations and our results obtained from our current studies led us to our hypothesis that 
combined Delta-24-RGDOX and IDO inhibitor treatment would increase T cell functions against 
viral and tumor antigens compared to the single agent treatments. Thus, to confirm our hypothesis 
we conducted ex vivo/in vivo co-culture experiments, where target parental cancer cells (mock 
infected or Delta-24-RGDOX infected) were cultured with splenocytes from the differently 
treated glioblastoma-bearing treated mice. Using the supernatants from these co-cultures, we 
performed ELISAs to detect levels of different T-cell activation cytokines, including IFNγ and 
IL-2. To determine T-cell function in the context of IDO activation, we also tested the secretion 
of IFNγ and IL-2 of these co-cultures in the presence of Kyn. Additionally, we used cells that 





Based on our previous studies and supporting data, we expected the following: 
1) Compared to splenocytes from PBS treated glioma bearing mice, splenocytes from 
Delta-24-RGDOX treated mice will yield higher levels of IFNγ and IL-2 when co-
cultured with mock or virally infected target cells.  
2) The levels of IFNγ and IL-2 will be even higher in co-cultures of splenocytes from 
mice treated with combined Delta-24-RGDOX and IDO inhibitor treatment.  
3) The levels of IFNγ and IL-2 will decrease in cultures that contained Kyn or targets that 






Combined IDO inhibition and Delta-24-RGDOX increases T-cell activation against tumor and 
viral antigen.  
To study the functional modifications of T cells in response to treatment, the activity of 
the systemic lymphocyte population was assessed by detecting the secretion of the Th1 cytokines, 
IFN and IL-2, by splenocytes from GL261-5-bearing mice treated with PBS, Delta-24-RGDOX, 
Indoximod, or combined Delta-24-RGDOX and Indoximod stimulated with tumor and/or viral 
antigens. Specifically, as outlined in Figure 29B, C57BL/6 mice were implanted with 5 × 104 
GL261-5 cells and underwent indicated treatment at specified times; mice were then sacrificed on 
day 24 to permit analysis of T-cell function. The splenocytes from these differently treated mice 
were cultured in the presence of different groups of target cells including mock infected GL261-
5 cells or Delta-24-RGDOX-infected GL261-5 cells. It was noteworthy that among splenocytes 
cultured with mock-infected GL261-5 cells, secretion of IFNγ and IL-2 was enhanced in 
splenocytes derived from mice previously infected with Delta-24-RGDOX compared to mice 
previously treated with PBS or Indoximod alone (p < 0.05, both groups), as seen in Figure 29C. 
Activation, via IFNγ and IL-2 secretion, is further enhanced against the tumor antigens (Mock 
GL261-5 Target Cells) in splenocytes from mice previously treated with the combination of 
Delta-24-RGDOX and Indoximod compared to Delta-24-RGDOX alone (Figure 29C, IFNγ, p = 
0.0157; IL-2 p = 0.0333). Similarly, the highest amount of secretion of IFNγ and IL-2 against the 
Delta-24-RGDOX infected target cells comes from the splenocytes from mice were treated with 
combined Delta-24-RGDOX and Indoximod (Figure 29D). These results suggested that 
splenocytes not only are activated against viral antigens but also recognize tumor antigens.  
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We performed a similar experiment as described above to study the T-cell function at 15 
days in the same GL261-5 model to study this effect over time. In splenocytes cultured with mock-
infected GL261-5 target cells, the trends in IFNγ secretion on day 15 were similar to those on day 
24 (Figure 30B), where we saw highest amount of IFNγ secretion in splenocytes that came from 
combination-treated mice when cultured with mock infected GL261-5 cells. Interestingly, as seen 
in Figure 30C, when the splenocytes were cultured with Delta-24-RGDOX infected GL261-5 
cells, levels of IFNγ secretion were higher on day 15 than on day 24 by nearly 10-fold in the 
splenocytes from Delta-24-RGDOX-treated or combination-treated mice. Moreover, on day 15, 
the levels of IFNγ secretion were similar in splenocytes from Delta-24-RGDOX-treated and 
combination-treated mice; notably, the secretion values in these splenocytes were about 50 times 
as high as the values in splenocytes from control and Indoximod-treated mice. This could indicate 
an early robust anti-viral immune effect and perhaps the conversion to a relatively less immune-
activating environment generated by clearance of the virus and complete tumor eradication by 
day 24. Overall, these functional studies showed that lymphocytes from the combination treated 
mice recognized not only viral antigens but also tumoral antigens, suggesting the triggering of 
anti-tumoral immunity. 
We next performed experiments using the GSC-005 C57BL/6 murine glioma model. As 
outlined in Figure 31B, C57BL/6 mice were implanted with 5 × 104 GSC-005 cells and underwent 
indicated treatment at specified times; mice were then sacrificed on day 24 to permit analysis of 
T-cell function. As seen in Figure 31, on day 24, splenocytes from the combination-treated mice 
secreted highest levels of IFNγ compared to splenocytes from all other groups when stimulated 
GSC-005 cells that were treated with a mock infection (Figure 31C, p = 0.0003) or treated with 
BGB-7204 and infected with Delta-24-RGDOX (Figure 31E, p = 0.0003). These data 
complement the data seen with the GL261-5 model and suggests the enhanced T-cell function in 
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splenocytes of mice that were treated with combined IDO inhibitor and Delta-24-RGDOX 
treatment compared to either treatment alone.  
 
Kyn or constitutive IDO expression negatively regulates T-cell activation against tumor and viral 
antigen. 
Because kynurenine has been reported to be involved with immunosuppression, we then 
wanted to dissect the role of kynurenine on T-cell activation using this same assay. To test this 
theory, we performed similar functional co-culture assays with kynurenine added to the cultures. 
Specifically, in a separate animal experiment, C57BL/6 mice were bolted on day -7, implanted 
with 5x104 GSC-005 cells on day 0, and split into two groups that included PBS or Delta-24-
RGDOX (1x108 pfu/mouse on days 7, 10, and 13). On day 15, mice were sacrificed, and 
splenocytes were then stimulated with pre-fixed uninfected (Mock) (Figure 32A/B left) or Delta-
24-RGD infected (Figure 32A/B right) GL261 (Figure 32A) or GL261-IDO-OE cells (Figure 
32B); an additional group that also contained kynurenine within the media was added. As 
expected, as seen in Figure 32A, the secretion of IL-2 was increased in splenocytes that came 
from Delta-24-RGD infected mice compared to PBS treated mice when cultured with either the 
mock infected or Delta-24-RGD infected GL261 cells (p=0.0039, p=0.0490, respectively), 
indicating the T cell activation against both tumor and viral antigen generated by Delta-24-RGD. 
Interestingly, when kynurenine was added to the cultures containing Delta-24-RGD treated 
splenocytes, the secretion of IL-2 was significantly reduced, suggesting the anti-tumor effect 
generated by kynurenine (mock GL261 target, p=0.0381; Delta-24-RGD infected GL261 target, 
p=0.0446). When these same experiments were done using the GL261-IDO-OE target cells, as 
seen in Figure 32B, the secretion of IL-2 of splenocytes from Delta-24-RGD infected mice when 
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cultured with the mock GL261-IDO-OE or Delta-24-RGD infected GL261-IDO-OE was either 
unchanged or diminished, respectively, compared to splenocytes from PBS treated mice. 
Furthermore, the IL-2 secretion of co-cultures containing either mock infected GL261-IDO-OE 
or Delta-24-RGD infected GL261-IDO-OE target cells with Delta-24-RGD treated splenocytes 
were significantly decreased when kynurenine was added to the cultures (mock target, p = 0.0355, 
Delta-24-RGD target, p = 0.0271), reinforcing the claim that the anti-tumor immune effect can be 
generated by kynurenine. Of note, the magnitude of IL-2 levels is decreased in the co-cultures 
that involved GL261-IDO-OE compared to WT GL261 co-cultures, suggesting the negative 
regulation of T-cell activation by constitutive IDO overexpression. Overall, these experiments 
elucidate the complex relationship between IDO, Kyn, and viral infection on the immune response 





Figure 29: Indoximod combined with Delta-24-RGDOX treatment increases T-cell 
activation against glioma and viral antigen.  
Panel (A) shows a schematic of the IDO-Kyn-AhR circuit. Panel (B) shows the schematic of 
experimental timeline, where mice were bolted on day -7, implanted with the 5x10
4
 GL261-
5 cells on day 0, injected with Delta-24-RGDOX (5x10
7
 pfu/mouse in 5µL) or PBS on days 
7, 9, and 11, and/or treated with 275 mg/kg per mouse of Indoximod on days 7-24. Mice were 
sacrificed on day 24, and splenocytes were isolated from these GL261-5 bearing mice that 
were treated with PBS, Indoximod, Delta-24-RGDOX, or combined Indoximod and Delta-
24-RGDOX and stimulated with prefixed GL261-5 cells that were (C) uninfected (mock 
infection) or (D) infected with Delta-24-RGDOX. Forty-eight hours later, the concentration 
of IFNγ (C/D left) or IL-2 (C/D right) in the co-culture supernatant was assessed by ELISA.  
Column graphs show mean pg/mL (n=3). I.C., intracranial. I.T., intratumoral. OG, oral 
gavage. BID, bis in die, twice daily. 
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Figure 30: Indoximod combined with Delta-24-RGDOX treatment increases T-cell 
activation against glioma antigen at an early timepoint. 
Mice were bolted on day -7, implanted with the 5x10
4
 GL261-5 cells on day 0, injected with 
Delta-24-RGDOX (5x10
7
 pfu/mouse in 5µL) or PBS on days 7, 9, and 11, and/or treated with 
275 mg/kg per mouse of Indoximod on days 7-24. Mice were sacrificed on day 15, and 
splenocytes were isolated from these GL261-5 bearing mice treated with PBS, Indoximod, 
Delta-24-RGDOX, or combined Indoximod and Delta-24-RGDOX and stimulated with 
prefixed GL261-5 cells that were (B) uninfected (mock infection) or (C) infected with Delta-
24-RGDOX. Forty-eight hours later, the concentration of IFNγ in the co-culture supernatant 
was assessed by ELISA.  Column graphs show mean pg/mL IFNγ (n=3). I.C., intracranial. 
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Figure 31: BGB-7204 combined with Delta-24-RGDOX increases T-cell activation 
against glioma and viral antigen.  
Panel (A) shows a schematic of the IDO-Kyn-AhR circuit. Panel (B) shows the schematic of 
experimental timeline, where mice were bolted on day -7, followed by injection of 5x104 
GSC-005 cells on day 0. On day 7, mice were split up into three treatment groups including 
BGB-7204 alone, Delta-24-RGDOX alone, or combined BGB-7204 and Delta-24-RGDOX. 
Mice received Delta-24-RGDOX (2.5x107 pfu/mouse) on days 9 and 11. BGB-7204 
treatment started on day 7 at a dose of 100 mg/kg twice daily and lasted until day 24, when 
we sacrificed the mice. Splenocytes from the differently treated mice were stimulated with 
pre-fixed GSC-005 cells that were (C) mock infected, (D) infected with Delta-24-RGDOX, 
or (E) treated with BGB-7204 and infected with Delta-24-RGDOX. Forty-eight hours later, 
the concentration of IFNγ in the co-culture supernatant was assessed by ELISA (R&D 
Systems).  The column graphs show of mean pg/mL of IFNγ (n=3). I.C., intracranial. I.T., 
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Figure 32: Kyn or constitutive IDO expression negatively regulates T-cell activation 
against glioma and viral antigen.  
C57BL/6 mice were bolted on day -7, implanted with 5x104 GSC-005 cells on day 0, and 
split into two groups that included PBS or Delta-24-RGDOX (1x108 pfu/mouse on days 7, 
10, and 13). On day 15, mice were sacrificed, and splenocytes were then stimulated with pre-
fixed (A and B left) uninfected (Mock) or (A and B right) Delta-24-RGDOX infected A) 
GL261 or B) GL261-IDO-OE cells; an additional group that also contained 25 µM 
kynurenine was added. Forty-eight hours later, the concentration of IL-2 in the co-culture 
supernatant was assessed by ELISA (R&D Systems). All column graphs show mean pg/mL 
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The results of this dissertation thus far have strengthened our rationale to combine IDO 
inhibitors with Delta-24-RGDOX for the treatment of murine glioma. We have demonstrated that 
Delta-24-RGDOX induces IDO expression and activation and increases T cell infiltration within 
the glioma, which associated with a substantial survival effect in glioma bearing mice. The 
addition of an IDO inhibitor to Delta-24-RGDOX further enhances T cell infiltration, decreases 
immune tolerant populations, and provides even greater survival benefit in glioma bearing mice.  
 To further strengthen the rationale of our proposed therapy, we performed functional 
studies to determine how combined IDO inhibitor and Delta-24-RGDOX treatment in glioma 
bearing mice modulates T cell activation against both viral and glioma antigens. We further 
determined the effects of Kyn and constitutive IDO expression on the function of these T cells. 
Based off these studies, we can make the following conclusions: 
1) Increased T cell function against tumor and viral antigens, via elevated IFNγ and IL-
2 levels, from splenocytes of Delta-24-RGDOX treated glioma bearing mice was 
reproducible (91). 
2) T cell function against both viral and tumor antigens was enhanced in splenocytes from 
mice treated with combined Delta-24-RGDOX and IDO inhibitor treatment.  
3) The presence of Kyn and/or constitutive IDO expression diminished the oncolytic 
virus-induced T-cell function recognize viral and glioma antigen.  
Overall, these functional studies combined with results describes in this dissertation 
strongly validate the central hypothesis of this study, which stated that therapy of Delta-24-
RGDOX combined with an IDO inhibitor will stimulate a cytotoxic immune response and inhibit 
the suppressive immune response against the tumor cells providing a potential effective novel 
treatment for glioblastoma. 
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Chapter 11: List of Conclusions 
 
1. Delta-24-RGDOX reshapes the murine brain tumor microenvironment. 
2. Delta-24-RGDOX increases the predicted diversity and percentage of immune 
populations. 
3. Delta-24-RGDOX increases both immune-activating and immune-suppressing pathways. 
4. Delta-24-RGDOX induces expression of genes from the IDO pathway. 
5. IFNγ induces IDO expression in human glioma, murine glioma, and other cancer cells. 
6. Delta-24-RGDOX activates the AhR pathway in human cancer cells. 
7. Delta-24-RGDOX induces Ahr expression and translocation into the nucleus in human 
cancer cells.  
8. Delta-24-RGD or Delta-24-RGDOX induces IDO expression in vitro in murine 
glioblastoma models. 
9. Delta-24-RGD or Delta-24-RGDOX induces IDO expression and activation in vivo of 
murine models of cancer. 
10. Inhibition of IDO in vitro, does not alter viral infection, viral replication, or viral-induced 
cytopathic ability of Delta-24-RGDOX.  
11. There is a greater therapeutic effect of Delta-24-RGDOX compared to PBS in IDO-KO 
mice bearing glioma.  
12. Glioblastoma-bearing IDO-KO mice live longer than WT mice when treated with Delta-
24-RGDOX.  
13. Delta-24-RGDOX combined with Trp-Mimetic, 1MT or Indoximod, leads to a more 
robust decrease in tumor mass, provides a survival advantage, and induces anti-tumor 
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immunity compared to single agents in the treatment of murine brain tumors compared to 
Delta-24-RGDOX treatment alone.  
14. Delta-24-RGDOX combined with direct IDO enzyme inhibitor, BGB-7204, results in 
greater reduction of tumor size compared to single agents in murine glioblastoma 
compared to Delta-24-RGDOX treatment alone. 
15. The therapeutic efficacy of Delta-24-RGDOX or combined Delta-24-RGDOX and IDO 
inhibitor treatment in murine glioblastoma requires CD4+ T cell activity.  
16. Delta-24-RGDOX increases the immunogenicity of murine glioblastoma indicated by 
enhanced infiltration of both immune-activating and immune-suppressive populations.  
17. The combination of Delta-24-RGDOX with IDO inhibitors increases the frequency of 
intratumoral T cells in murine glioblastoma compared to Delta-24-RGDOX treatment 
alone. 
18. The combination of Delta-24-RGDOX with IDO inhibitors decreases the frequency of 
immune tolerant populations, including Tregs and MDSCs, within the murine 
glioblastoma microenvironment compared to Delta-24-RGDOX treatment alone. 
19. The use of IDO inhibitors alone in the treatment of murine glioblastoma provides minimal 
immunological responses and is associated with poor survival. 
20. Combined IDO inhibition and Delta-24-RGDOX increases T-cell activation against tumor 
and viral antigen in the setting of murine glioblastoma.  
21. Kyn or constitutive IDO expression negatively regulates T-cell activation against tumor 
and viral antigen in the setting of murine glioblastoma. 
22. The use of IDO inhibitors with armed oncolytic adenoviruses provides a potential and 




Chapter 12: Discussion 
 
Encouraging results from a phase III clinical trial led to the recent US Food and Drug 
Administration approval of the modified type 1 herpes simplex virus, Talimogene laherparepvec 
(T-VEC), for treatment of advanced melanoma (182) leading to a resurgence of interest in 
oncolytic viruses as a cancer therapy. There is particular interest of oncolytic adenoviruses in the 
treatment of glioma because of the convenience of administering the virus intratumorally during 
surgery. Currently, eight different families of viruses are being tested for the treatment of glioma. 
Overall, these studies have shown us that the treatment of oncolytic viruses results in minimal 
toxicity, increases immunogenicity, and can lead to long term survival in 6-25% of patients with 
recurrent glioma (90, 97-106, 108, 109, 122, 183). Of these studies, the predecessor of Delta-24-
RGDOX, Delta-24-RGD, resulted in 20% of patients surviving past three years. Exploratory 
objectives of this study showed anti-tumor responses via the elicitation of an immune response, 
as indicated by infiltration of T-bet+ CD8+ T cells and the pseudoprogression of a tumor post 
treatment before complete regression; this could imply initial generation of inflammation by the 
virus before the subsequent anti-tumor immune response (90). These observations support the 
emerging paradigm that oncolytic viruses are a type of immunotherapy. These clinical studies 
also reveal that single agent therapy of oncolytic viruses will most likely not result in maximal 
therapeutic benefits. Hence, we decided to combine Dellta-24-RGDOX with IDO inhibitors for 
the treatment of glioblastoma based on observations that 1) IDO is commonly upregulated after 
viral infection (58, 66, 166, 170, 184, 185) and 2) IDO causes immunosuppression conducive to 
tumor growth (28, 32, 186-188).  
Our previous studies show that Delta-24-RGDOX elicits a more potent anti-tumor 
immune and immune memory response compared to Delta-24-RGD, leading to more survival of 
glioma bearing mice (91). The enhanced immune effect, as evidenced by increased infiltration, 
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activation, and memory of lymphocytes within the tumor microenvironment is provided by 
activation of the OX40 pathway of the effector T cell via Delta-24-RGDOX induced OX40L 
expression on cancer cells (91). These data supported the start of a phase I clinical trial testing 
Delta-24-RGDOX on patients with recurrent glioblastoma in Spain (NCT03714334). Despite 
these directed anti-tumor immune responses by Delta-24-RGDOX, maximal therapeutic benefits 
were never achieved, signifying the presence of a sustained negative regulation of immune 
activation against the tumor. Interestingly, the RNA sequencing results revealed that in the 
GL261-5 murine glioblastoma model, Delta-24-RGDOX reshaped the tumor microenvironment 
producing the upregulation of genes involved in both immune activating and immune suppressive 
pathways. Of significance, Delta-24-RGDOX treated brain tumors showed enrichment of the IDO 
pathway and its related cell targets, Tregs and MDSCs. Furthermore, the RNA sequencing 
analyses revealed elicitation of common immune checkpoint proteins including CTLA-4 and PD-
1. This result validated our previous studies showed that the combination of Delta-24-RGDOX 
and anti-PD-L1 provided a greater survival benefit compared to Delta-24-RGDOX alone in the 
GL261-5 murine glioblastoma model (91). Collectively, these data support the ongoing clinical 
trial testing the treatment of patients of recurrent glioblastoma with Delta-24-RGD and 
pembrolizumab (anti-PD-1) (NCT02798406). The RNA sequencing analyses also validated our 
quantitative PCR studies that showed this phenomenon of negative immune regulation elicited by 
Delta-24-RGDOX infection, where IDO expression increased in the GL261-5 murine 
glioblastoma model and the unrelated 4T1.2 murine breast cancer model in response to the viral 
infection.  
Activation of IDO by Delta-24-RGDOX was also evident in the GL261-5 and GSC-005 
murine glioblastoma models. Furthermore, even when we remove the immune component, Delta-
24-RGDOX can still increase the expression of IDO and AhR in cancer cells in vitro, indicating 
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an IFNγ-independent mechanism of IDO induction by Delta-24-RGDOX; correspondingly, we 
observed the activation and translocation of AhR from the cytoplasm to the nucleus in these virally 
infected tumor cells. Importantly, IDO and AhR overexpression is implicated in brain 
malignancies (23, 189). These data provided the rationale supporting the combination of Delta-
24-RGDOX and IDO inhibitors for the treatment of murine glioma.  
Thus, to increase the anti-tumor immune effect of Delta-24-RGDOX, we tested the 
addition of IDO inhibitors in two immunocompetent murine glioma models, GL261-5 and GSC-
005. We demonstrated the survival advantage or complete tumor eradication by the combination 
treatment of IDO inhibitor and Delta-24-RGDOX over single-agent treatments in both models. 
We reproduced these results in the highly aggressive B16 murine melanoma intracranial tumor 
model. These data are consistent with our additional survival data in the GSC-005 model, where 
we observed long term survival of IDO-KO mice compared to WT mice following intratumoral 
administration of Delta-24-RGDOX; importantly, this result exhibits the on-target effect of IDO 
inhibition and its enhanced therapeutic effect when combined with Delta-24-RGDOX. However, 
we must note here that the survival curve of the combination of IDO inhibitor and Delta-24-
RGDOX we observed in the GL261-5 model was not similar to the survival curve of the GL261-
5 bearing IDO-KO mice treated with Delta-24-RGDOX. Here, there are a couple considerations 
to make: first, the viral dose in the IDO-KO experiment was lower, and second, we used 
Indoximod to test the therapeutic efficacy of its combination with Detla-24-RGDOX. Indoximod 
is not considered a direct enzyme inhibitor; instead, it provides a Trp sufficiency signal to reverse 
stress kinase signals that can inhibit mTORC signaling in surrounding T effector cells (27). 
Further studies testing direct IDO inhibitors in the GL261-5 model will be required to determine 
the therapeutic efficacy of direct IDO inhibitors in the context of direct IDO enzyme inhibitors. 
Notably, we still see viral-induced cytopathic ability of Delta-24-RGDOX in cases of IDO 
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inhibition, such as with the IDO inhibition in vitro by BGB-7204 or in the extreme case of IDO 
inhibition in GSC-005 or GL261-5 bearing IDO-KO mice. Overall, these results indicate that 
combined IDO inhibition and oncolytic adenoviral treatment presents no unwanted drug 
interactions and highlight the potential therapeutic effects that can be seen in patients if treated 
with this drug combination.  
Our studies displayed that Delta-24-RGDOX transformed the murine glioblastoma from 
a non-immunogenic to an immunogenic tumor, as indicated by an influx of CD3+ T cells and 
other immune cells evident by our histopathological analysis and flow cytometry assays. This 
conversion of immunogenicity by Delta-24-RGDOX increased the amounts of both activating and 
immunosuppressive immune populations, which provided a target for the Indoximod or BGB-
7204 to work as intended. Furthermore, we showed that both Delta-24-RGD and Delta-24-
RGDOX could induce IDO expression and activation in the tumor cells, most likely through an 
IFN-dependent mechanism, and thus increasing the likelihood of response to the IDO inhibitor. 
Related to our study, Ladomersky et al. recently reported a durable survival benefit in the GL261 
immunocompetent murine glioma model with the triple combination of CNS-penetrating IDO1 
enzyme inhibitor, BGB-5777 (39)  or BGB-7204 (57), anti-PD1 mAb, and radiotherapy; in that 
study, the radiotherapy generated an immunogenic tumor, allowing the targets of the IDO enzyme 
inhibitor and the anti-PD1 mAb to be exposed. These and our results are consistent with the 
concept described by Sharma and Allison (41) that if a non-immunogenic tumor becomes 
immunogenic, it should become more responsive to immunotherapy. 
To our knowledge, our study is the first to report the efficacy of combining IDO inhibitors 
and an armed oncolytic adenovirus in a murine glioblastoma model. In agreement with our study, 
Berrong et al. recently reported an enhanced survival effect with addition of Trp-mimetic, 
Indoximod, to the combination of an anti-OX40 agonist and a vaccine against HPV16 E7 in an 
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HPV16-E6-E7/HRAS–driven lung epithelial cancer model (190). This result validates our 
studies, which shows that IDO inhibition enhances the anti-cancer effects of OX40 activation. 
This study also supports that this anti-cancer effect generated by the therapeutic strategy of 
combined IDO inhibition and OX40 pathway activation is not limited to the treatment of glioma. 
In contrast with the use of cancer vaccines, the use of oncolytic viruses does not require previous 
knowledge about the tumor antigen load since the oncolytic virus can infect and lyse all RB-
deficient cells to release tumor-associated antigens into the tumor microenvironment. Consistent 
with the effects of their triple combination, we observed both a reduction in regulatory T cells and 
an increase in CD8+ T cells in the tumors of mice treated with Delta-24-RGDOX and 
Indoximod/BGB-7204.  Furthermore, Berrong et al. showed an increase in tumor-antigen-specific 
CD8+ T cells, which is consistent with our co-culture experiments in which we found increased 
IFNγ and IL-2 responses against both viral and tumor antigens in splenocytes from brain tumor–
bearing mice treated with combined Delta-24-RGDOX and Indoximod/ BGB-7204. This result 
also suggests the generation of a tumor-specific immune memory, as these splenocytes were 
presented with the same cancer antigens after being extracted from the mouse in an ex vivo setting. 
This finding, along with our discovery of 100% survival in re-challenged GL261-5-bearing mice 
previously treated with combined Delta-24-RGDOX and Indoximod, strongly indicates the 
presence of a tumor-specific immune memory generated by the combination treatment. These 
results emphasize the importance of the host immune system for the development of therapeutic 
efficacy and memory against tumor antigen. Similarly, the results from our CD4+ T cell depletion 
survival experiment in the GL261-5 model revealed the requirement of the CD4+ T cell population 
on the therapeutic efficacy of the combined Delta-24-RGDOX and IDO inhibitor treatment. 
 Our studies also demonstrate the antitumor immunosuppression generated via the IDO-
Kyn circuitry in the context of oncolytic adenoviral infection. That is, the presence of Kyn was 
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able to decrease the T-cell activation against both tumor and viral antigen that was generated by 
the oncolytic virus. Consistently, T-cell activation generated by the oncolytic virus was reduced 
in the presence of targets that constitutively overexpress IDO compared to IDO-WT targets. This 
result led to the speculation that that the IDO-Kyn pathway aids in negative regulation of anti-
tumor immunity during virotherapy, and it can be reversed with the use of IDO inhibitors.  
The murine glioblastoma models utilized in this study do not express IDO. Thus, the 
effects of the IDO inhibitor are presumably due to changes of the host immune tumor 
microenvironment. The literature shows that IDO can be expressed by dendritic cells and 
macrophages (147), but we did not identify the source of IDO in our model; doing so, through the 
use of CyTOF or RNA sequencing of the brain tumors of differently treated mice, might elucidate 
how our virus can alter IDO expression in different immune cell populations to produce more 
immunosuppression within the tumor microenvironment. Still, our studies show that Delta-24-
RGDOX or IFNγ can increase the expression of IDO in vitro in different murine and human 
glioma cells. Additionally, the infection of Delta-24-RGDOX in human cancer cells increased 
AhR activity and its translocation into the nucleus, suggesting that activation of IDO, whose 
catabolite, Kyn, is an agonist for AhR. AhR has been reported to cause immunosuppression in 
glioblastoma via activation of Tregs (32, 33), induction of either apoptosis or dysfunction of 
effector CD8+ T-cells, or activation of immunosuppressive macrophages and other population of 
immune cells causing immunosuppression (46). This activation of IDO and AhR in the tumor 
microenvironment cooperate to suppress tumor-specific immune responses, promoting glioma 
immune evasion and tumor progression (32, 33).  Importantly in our study, in addition to the 
Delta-24-RGDOX induced AhR expression and activity in vitro, the in vivo brain tumors from 
the virus-infected groups expressed and activated more IDO compared to control-treated mice, 
indicating that the tumor microenvironment of this model contained an active IDO that could be 
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involved in the subsequent activation of the Kyn-AhR cascade. Consistent with the negligible 
levels of IDO or Kyn in PBS treated brain tumors, Treg and MDSC populations were nearly 
undetectable in these samples of the GL261-5 model. Upon treatment with Delta-24-RGDOX, the 
brain tumors displayed increases in the Treg and MDSC populations. This result was validated by 
our RNA sequencing analyses that showed enrichment of the Treg and MDSC gene sets in Delta-
24-RGDOX murine brain tumors. When IDO inhibitors were combined with Delta-24-RGDOX, 
the Treg and MDSC populations were diminished. These data are consistent with the new 
paradigm of viro-immunotherapy, which supports the theory of oncolytic viruses transforming 
immune-excluded tumors to more immunogenic one. Moreover, the subsequent decrease of the 
Treg and MDSC populations when an IDO inhibitor is added to Delta-24-RGDOX underline the 
ability of these inhibitors to decrease immunosuppressive populations.  
In conclusion, we have shown for the first time that combined treatment with Delta-24-
RGDOX and IDO inhibitors produces long-term survival in a murine glioblastoma model without 
any observable toxic effects. We further shown that this effect may be mediated by an increase in 
cytotoxic T-cell activity, a decrease in immunosuppressive immune populations, and subsequent 
generation of anti-glioma immune memory.  This highly translatable study strongly suggests that 
the use of IDO inhibitors with armed oncolytic adenoviruses will be a promising treatment for 




Chapter 13: Future Directions 
 
The studies of this dissertation have shown that the modified oncolytic adenovirus armed 
with OX40L, or Delta-24-RGDOX, can induce the expression and activation of the IDO pathway 
upon infection of murine glioblastoma, a result that validated observations made from RNA 
sequencing analyses. Further RNA sequencing analyses demonstrated that Delta-24-RGDOX 
elicited expression of both Th2 and Th1 responses, which could explain the modest survival of 
glioma bearing mice (191). We demonstrated that combined Delta-24-RGDOX and IDO inhibitor 
treatment increases survival and aids in complete tumor regression of glioma bearing mice. This 
antitumor effect was most likely due to enhanced anti-tumor and decreased immune suppressive 
responses, most likely through a skewed Th1 response provided by the IDO inhibitor when added 
to Delta-24-RGDOX (27, 39, 52, 190). This was evidenced by more infiltration of CD3+, CD4+, 
and CD8+ T cells compared to the single treatment of Delta-24-RGDOX. Exploration of the 
systemic splenocytes revealed that the combined Delta-24-RGDOX and IDO inhibitor treatment 
led to enhanced T cell responses against tumor and viral antigens compared to Delta-24-RGDOX 
alone, and that Kyn was able to reverse these T cell responses. Furthermore, the treatment of these 
mice with Delta-24-RGDOX increased immune tolerant populations, Tregs and MDSCs, and 
were decreased in the tumor microenvironment when an IDO inhibitor was added. This current 
model is summarized in Figure 33.  
Although these studies provide a significant rationale to combine IDO inhibitors with 
armed oncolytic adenoviruses in the clinic, there is still much to be discovered regarding the basic 
interactions of OX40, IDO, and AhR. There are few reports studying pathways of this tumor 
necrosis superfamily and its direct effects on IDO and AhR signaling and vice versa (190, 192). 
Studied separately, the consensus of IDO and AhR signaling in glioblastoma, is that it aids in a 
tumor tolerant microenvironment (26, 189). Elucidation of the detailed biological underpinnings 
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of OX40, IDO, and AhR signalling within the glioma microenvironment would yield valuable 
insights into potential druggable targets that could be applied to the treatment of glioma. 
Furthermore, our studies focused only on the use of IDO inhibitors. Very few AhR antagonists 
are being studied pre-clinically and clinically (189, 193). We propose that additional studies using 
AhR inhibitors will clarify which arm of the IDO-Kyn-AhR cascade causes more 
immunosuppression within the tumor, which will provide a strong basis for the translation of IDO 
or AhR inhibitors in combination with armed oncolytic adenoviruses into the clinic. We also 
expect that new IDO and AhR inhibitors will arrive to the clinical arena soon and that their 
addition to virotherapy might result in the improvement of the prognosis of patients with brain 
tumors and other solid tumors. 
Three clinical trials are determining the safety profile of combining Indoximod with 
chemotherapy and/or radiation in adult and pediatric patients with recurrent glioma 
(NCT02052648, NCT04049669, NCT02502708) are currently underway. Similarly, we propose 
to translate the combination of Delta-24-RGDOX and Indoximod into a phase I clinical trial to 
first determine the safety profile of the drug combination in patients with recurrent glioblastoma. 
We predict that this combined therapy of Indoximod and Delta-24-RGDOX will improve the 




Figure 33: The immunological effects of Delta-24-RGDOX combined with IDO inhibitors 
within the glioma microenvironment.  
The microenvironment of gliomas is characterized by a paucity of T cells skewed towards the 
Th2 phenotype. This Th2 phenotype promotes IL-4 function and recruitment of MDSCs, 
Tregs, or anergic PD-1+ or CTLA-4+ T cells. Infection of gliomas with oncolytic viruses, such 
as Delta-24-RGDOX, results in the induction of a Th1 phenotype with an increase of the 
production of IL-12 or IFNγ. However, the viral infection activates both the IFNγ-driven IDO-
Kyn-AhR cascade and the maintenance of immune suppression via activation of MDSCs and 
Tregs. The addition of IDO inhibitors to virotherapy results in an imbalance of the signaling 
with a predominance of Th1 and CD8+ cytotoxic T cells leading to the eradication of the tumor. 
Figure created with BioRender.com. 
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